Characterization of long-lasting lung resident cells taking up and retaining antigen for extended period of time by Karabeg, Adela
 
 
 
 
 
 
 
 
DIPLOMARBEIT 
 
 
 
 
 
 
 
CHARACTERIZATION OF LONG-LASTING LUNG 
RESIDENT CELLS TAKING UP AND RETAINING 
ANTIGEN FOR EXTENDED PERIOD OF TIME 
 
 
 
 
 
 
 
Magistra der Pharmazie (Mag.pharm.) 
 
 
 
 
 
Verfasserin / Verfasser: Adela Karabeg 
Matrikel-Nummer: 9903445 
Studienrichtung (lt. Studienblatt): Pharmazie 
Betreuerin / Betreuer: Univ.-Prof. Dr. Oskar Hoffmann 
 
 
 
 
Wien, 07.11.2008 
 
 

 
 
 
 
 
 
 
An dieser Stelle danke ich Herrn Professor Dr. Oskar Hoffmann und Dr. Michelle M. 
Epstein für die Aufnahme in ihre Arbeitsgruppe, für die wertvollen Ratschläge und 
Fachgespräche sowie für ihre persönliche Unterstützung. 
 
Ein großes Dankeschön für die geduldige Einführung in den Laboralltag und das 
angenehme Arbeitsklima geht an Rashmi Bankoti, Hannelore Kadlec, und insbesondere 
an Pallavi Singh, für ihre unermüdliche Hilfsbereitschaft sowohl bei der Durchführung 
der Laborarbeiten und Erstellen dieser Arbeit, als auch außerhalb der Laborwände, wo 
sie mir stets zur Seite stand.  
 
Mein Dank gebührt auch meinen treuen Freunden Iva und Michael Wagner, Mukadesa 
Ustović, Jasna Klačar, Krassimire Nestorov sowie der Familie Talić. Bei ihnen und 
jenen anderen, die mich in meiner Studienzeit begleitet haben, bedanke ich mich 
herzlichst für den tatkräftigen Beistand, offene Ohren und Zuspruch.  
 
Doch vor allem danke ich meinen Eltern und der Familie für ihre unendliche 
Unterstützung in jeder Hinsicht, für ihre Geduld und Motivation in all den Jahren.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
ABSTRACT 
 
 
 
Allergic asthma is a chronic disorder of the respiratory tract characterized by airway 
inflammation, mucous hyperproduction and bronchial hyperresponsiveness. Clinical 
manifestation in patients includes coughing, wheezing, shortness of breath and chest 
tightness. The gravity of symptoms is perceptible particularly during the night or in the 
morning.  
 
Despite the progress in understanding the underlying mechanisms and nature of asthma-
drivers, the prevalence of the disease has continuously increased over the last decades.  
On a biological level, it is an immunological reaction to certain invading agent that is 
orchestrated by diverse elements including immune as well as structural cells as well as 
their products. Raising evidence suggest the key role of antigen presenting cells (APC), 
primarily of dendritic cells (DC), in the pathobiological process of asthma. Indeed, 
APCs are the first players upon encounter to an antigen and thus they are essential for 
the sensitization and subsequent immune responses. In other words, APCs are pivotal 
for initiation and development of pulmonary inflammation.  
 
In this study, a novel cell population with attributes of APC that picks up Ag and stores 
it for prolonged period of time was characterized. Naïve mice and those rechallenged 
with Ag to induce exacerbations vs mice recovered from a single episode of allergic 
asthma were used in these studies. The naïve group were healthy animals that had never 
encountered OVA, whereas rechallenged and recovered mice were those with only one 
experimentally induced episode of allergic asthma. Animals in latter two groups were 
systemically immunized with OVA on 2 separate occasions and subsequently exposed 
to aerosolized OVA. In the further course of the project, mice belonging to naïve as well 
as the rechallenged group received intranasal instillation of OVA conjugated to a red 
fluorochrome TexasRed (TR-OVA). Recovered rodents, by contrast, were excluded 
from i.n. treatment with TR-OVA and had to rest for few months in order to recuperate 
from the disease. Ag capture and retention in lung cells of naïve and rechallenged mice 
was visualized with methods of immunofluorescence. Further immunohistochemical 
analysis provided specification concerning their morphology, localization and possible 
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function. According to cell surface markers they either do or do not express, a 
phenotype of this cell subset was established.  
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ZUSAMMENFASSUNG 
 
 
Allergisches Asthma ist eine chronische Erkrankung der Atemwege, gekennzeichnet 
durch Entzündung, Überproduktion von Schleim und bronchiale Hyperreagibilität. 
Klinisch manifestieren sich diese Prozesse in Form von Husten, Niesen, Atemlosigkeit 
sowie beklemmendem Gefühl in der Brust.  
 
Auch der kontinuierliche Fortschritt und die Gewinnung neuester Erkenntnisse im 
Zusammenhang mit den zugrunde liegenden Mechanismen der Krankheit konnten dem 
Ausbreiten von Asthma nicht halt bieten.  
Biologisch gesehen handelt es sich um eine Überreaktion des Immunsystems auf 
gewisse körperfremde, ansonsten oft harmlose Substanz. Die immunologische Antwort 
wird dabei sowohl von Immun- als auch von Gewebszellen samt ihren Produkten 
vermittelt. Bedeutende Evidenzen weisen in diesem Sinne auf die zentrale Rolle der 
antigen-präsentierenden Zellen hin, insbesondere richtet sich das Augenmerk der 
Forscher auf die dendritischen Zellen. Denn, die antigen-präsentierenden Zellen sind die 
ersten, die die eingedrungenen Allergene abfangen. Daher bilden sie die notwendige 
Basis für die Sensibilisierungsprozesse und die darauf folgenden Immunantworten, 
sprich, sie sind ausschlaggebend für die Entstehung und Entwicklung der 
Atemwegsentzündung.  
 
In dieser Studie wurde eine neue Lungenzellpopulation untersucht, die Antigene 
aufnimmt und sie gewisse Zeit bewahrt, eine Population also, die Eigenschaften der 
antigen-präsentierenden Zellen aufweist. Naive Mäuse und solche mit der Erkrankung, 
sowie die von den Asthmasymptomen erholten Mäuse dienten als Probanden. Die 
naiven „Modelle“ wurden von den Tieren repräsentiert, die bis dato keinerlei Kontakt 
mit dem OVA-Antigen hatten. In den erkrankten und erholten Tieren hingegen wurde 
auf experimentellem Wege allergisches Asthma induziert. Dazu wurden sie einer 
systemischen Immunisierung mit OVA zu zwei verschiedenen Zeitpunkten unterzogen. 
Anschließend wurden sie mit aerosolisiertem OVA behandelt. Im weiteren Verlauf 
wurde den naiven sowie erkrankten Mäusen das mit rotem Fluorochrom (Texas Red) 
konjugierte OVA-Antigen intranasal verabreicht (TR-OVA). Erholte Tiere waren 
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hievon ausgeschlossen und bildeten somit die Kontrollgruppe. Das rote TR-OVA 
Antigen konnte letztendlich in den Lungen nachgewiesen werden. Die Zellen, die es 
aufgenommen hatten, wurden mithilfe von Immunfluoreszenz-Techniken visualisiert. 
Die daraufhin  folgende immunohistochemische Analyse führte zu einer umfassenden 
Charakterisierung hinsichtlich ihrer Morphologie, Lage in der Lunge und der möglichen 
Funktion. Aufgrund dieser Daten und entsprechend ihres Oberflächenmarker-Profils 
wurde der Phänotyp dieser Zellpopulation erstellt.  
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ABBREVIATIONS 
 
 
Ab  Antibody 
Ag  Antigen 
AHR  Airway hyperresponsiveness 
Alum  Aluminium sulfate 
APCs  Antigen presenting cells 
AR  Alexa Red 
BAL  Bronchoalveolar lavage 
BHR  Bronchial hyperresponsiveness 
CD  Cluster of differentiation 
CTLs  Cytotoxic T lymphocytes 
DC  Dendritic cells 
DT  Diphtheria toxin 
DTR  Diphtheria toxin receptor 
ECM  Extracellular matrix proteins 
FACS  Fluorescence Activated Cell Sorter  
FITC  Fluorescein isothiocyanate 
GFP  Green fluorescent protein 
GM-CSF  Granulocyte macrophage colony-stimulating factor 
HDM  House dust mite 
IFN  Interferon 
Ig  Immunoglobulin 
IL  Interleukin 
i.n.  intranasal 
i.p.  intraperitoneal 
LC  Langerhans cells 
LPS  Lipopolysaccharide 
MHC  Major Histocompatibility Complex 
mDC  Myeloid dendritic cells 
NK  Natural killer (cell) 
NO  Nitric oxide 
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OVA  Ovalbumin 
PAF  Platelet-activating factor 
PAMPs  Pathogen Associated Molecular Patterns 
PAS  Periodic acid-Schiff 
PBS  Phosphate buffered saline 
pDC  Plasmacytoid dendritic cells 
PGE2  Prostaglandin E2  
PMNs  Polymorphonuclear leukocytes 
PRR  Pattern Recognition Receptor 
TCR  T cell receptor 
TG  transgenic 
TGF  Transforming growth factor 
Th  T helper (cell) 
TNF  Tumour necrosis factor 
TR  Texas Red 
Tregs  Regulatory T cells 
WBC  White blood cells 
WBP  Whole-body plethysmography 
WT  Wild-type 
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1. INTRODUCTION 
 
 
1.1 INTRODUCTION TO THE IMMUNE SYSTEM 
 
Understanding of the human immune system has significantly advanced in the past few 
decades. 
 
The immune system is defined as a composition of mechanisms coordinated by cells, 
tissues and molecules that all together mediate resistance to infections, and its 
physiologic function is to prevent those infections and eliminate the established ones. 
This operation is expressed as the immune response and it is a corresponding reaction of 
the organized immune system components to infectious microorganisms. 
 
The significance of the immune system for health is well-founded by the fact that people 
with defective immune responses are susceptible to serious, often life-threatening 
illnesses. Paradoxically, the process of vaccination in order to stimulate immune 
responses and develop resistance against foreign pathogens is the most effective method 
for protecting individuals against infections. 
 
On the one hand, we have an irreplaceable and incomparable defence system, but on the 
other hand, the immune response is the major barrier to successful organ 
transplantations. 
 
Apart from that, the intention to treat cancers by stimulating immune responses against 
cancer cells are being implemented in different malignancies therapies (Abbas and 
Lichtman, 2009).  
Therefore, the awareness concerning the wide field of immunology is constantly 
increasing among both, scientists as well as general public.  
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1.1.1 Innate immunity 
 
The defence system is organized in two major subdivisions, the innate or nonspecific 
immune system, which mediates the initial protection against infections, and the 
adaptive or specific immune system, which develops more slowly and enables also 
protection against re-exposure to the same pathogen. The innate immune system is our 
first line of defence against invading organisms while the adaptive immune system acts 
as a second line of defence. Each of these subdivisions of the immune system has both, 
cellular and humoral components by which they carry out their protective function. In 
addition, the innate immune system also has anatomical features that behave as barriers 
to infection (Abbas and Lichtman, 2009; Janeway et al., 2002).  
Although these two branches of the immune systems both operate to protect against 
invading organisms, they differ in several ways. Innate, also called native immunity, is 
characterized by its constant presence in healthy individuals, ready to blockade the entry 
of pathogens and to rapidly eliminate those who do manage entering the organism. 
Unlike the adaptive, the innate immunity is not particularly specific and its components 
recognize structures that are represented by diverse classes of microbes. It reacts equally 
well to a variety of organisms and in case of repeated encounter with foreign pathogen 
the innate immunity responds in the same extent, what means it does not demonstrate 
immunological memory. And finally, the innate immune system does not react against 
itself or against nonmicrobial/non-infectious substances, in contrast to adaptive 
immunity (Abbas and Lichtman, 2009). For this reason people used to believe the innate 
immunity is not effective enough in eradicating most infections. In the meantime it is 
clear that there is interplay between these two systems and that innate host defence not 
only provides immediate protection but also instructs the adaptive defence mechanisms 
to respond effectively to various pathogens (Abbas and Lichtman, 2009; Janeway et al., 
2002).  
 
Components of innate immunity 
 
Epithelia, cells in tissue and circulation and different plasma proteins, these elements 
and their complementary manner represent the innate immune system (Abbas and 
Lichtman, 2009; Janeway et al., 2002).  
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Epithelial barriers 
 
The major portals of entry of microbes are the skin, gastrointestinal tract and respiratory 
tract. These openings are very tempting for microorganisms to invade the host, therefore 
they are surrounded by epithelia that forms a physical barrier which is impermeable to 
most pathogens. Thus, the skin acts as our first line of defence (Abbas and Lichtman, 
2009; Goldsby et al., 2001; Janeway at al., 2002). Furthermore the flushing action of 
tears, saliva and urine helps prevent infections of eyes, mouth and urogenital tract. 
Coughing and sneezing help our lungs keep the airways free from microbes. The 
trapping effect of mucus secreted by respiratory and gastrointestinal tract serves to 
protect lungs and digestive system from infections (Roitt et al., 1989).  
 
Another way to defend our body openings are chemical barriers. Fatty acids in sweat for 
example inhibit the growth of bacteria. Enzymes like lysozyme and phospholipase 
found in tears, saliva and nasal secretions are able to break the cell wall of bacteria and 
stop their multiplying. Respiratory tract produces peptides such as defensins, that have 
antimicrobial activity. In the stomach low pH due to gastric acid makes it impossible for 
many ingested pathogens to survive (Roitt et al., 1989).  
In the end, the normal flora of the skin and within the gastrointestinal and genitourinary 
tracts acts as a biological barrier by secreting toxic substances and competing with 
pathogenic agents for nutrients or attachment to cell surfaces (Roitt et al., 1989).  
 
 
Cells of innate immunity 
 
Cellular barriers, here leukocytes, are the main line of defence in the non-specific 
immune system. They are white blood cells (WBCs) and amongst others they include 
phagocytes, eosinophils, basophils, mast cells and natural killer cells, and they all are 
derived from common precursor cells: haematopoietic stem cells in bone marrow 
(Abbas and Lichtman, 2009; Janeway et al., 2002).  
Phagocytes themselves are classified into monocytes/macrophages, neutrophils and DC. 
All of them serve to recognize, identify and eliminate infectious agents, and additionally 
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they play a role in activation of the adaptive immune response (Abbas and Lichtman, 
2009; Janeway et al., 2002).  
Neutrophils and monocytes belong to circulating phagocytes and are recruited to the site 
of infection where they recognize and phagocytose microorganisms and kill them 
intracellularly. Neutrophils, so-called polymorphonuclear leukocytes (PMNS), are the 
most abundant leukocytes in the bloodstream. Their production is stimulated by 
cytokines, which are produced by many cells as a reaction to infection. They are usually 
the first cells to reach the place of infection. Neutrophils ingest pathogens in the 
bloodstream as well as in the extravascular tissues, where they survive for only few 
hours. 
Monocytes are not as numerous as neutrophils. In contrast to neutrophils, monocytes 
that migrate through blood vessel walls into extravascular tissues survive for longer 
periods and there, these monocytes differentiate into macrophages. In addition, the body 
has macrophages already stationed throughout the tissues and organs, thus these 
macrophages and blood monocytes are two families of the same cell lineage, namely 
mononuclear phagocytic system. Macrophages have a number of very important 
functions in body defence including: killing of microbes, infected cells and tumor cells 
by phagocytosis and processing antigens so they can be recognized by T-lymphocytes 
during the adaptive immune response. Because of this function they are often referred to 
as antigen-presenting cells (APCs). Furthermore macrophages produce and secrete 
diverse proteins called cytokines, growth factors and enzymes, which are significant for 
non-specific body defence (Janeway at al., 2002; Roitt et al., 1989). 
 
DCs are phagocytes located throughout the skin, respiratory and gastrointestinal tract as 
well as lymphoid tissues. The principal task of immature DCs is to capture antigens 
through pinocytosis and phagocytosis, leave their initial site, enter lymph vessels and 
migrate to lymph nodes. By the time they reach the lymph nodes, they have matured and 
are now able to present antigen to T-lymphocytes. Hence, DCs belong to APCs 
(Janeway at al., 2002). 
 
Mast cells are most often associated with allergy and anaphylaxis and they carry out 
many of the same inflammatory-mediating functions as basophils. There are two types 
of mast cells in the body: mast cells found in the connective tissue and those found 
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throughout mucus membranes. The granules of mast cells contain such mediators as 
histamine, eosinophil chemotactic factor, heparin, leukotrienes, platelet activating factor 
and cytokines. Apart from that they also synthetize prostaglandins, chemicals which 
promote inflammation (Roitt et al., 1989). 
 
Basophils make up a very small percentage of WBCs in the bloodstream. Like mast 
cells, basophils release histamine, leukotrienes, heparin and prostaglandins which boost 
inflammation by causing vasodilatation, increasing capillary permeability and 
increasing mucous production (Roitt et al., 1989). 
 
Eosinophils belong to leukocytes that play a significant part in allergic responses. The 
number of eosinophils in blood often rise above the normal range not only with allergic 
reactions but also upon parasitic infections like worms. They act as scavengers by 
destroying ingested microbes, however primarily they set their contents free in order to 
kill huge microorganisms extracellularly. Amongst others they release destructive 
enzymes for infectious organisms such as: acid phosphatase, peroxidases, major basic 
protein, RNase, DNases and other chemicals like leukotrienes and cytokines (Janeway 
et al., 2002; Roitt et al., 1989). 
 
Natural killer cells (NK cells) build up a small fraction of the lymphocytes in the blood 
that, unlike T- and B-lymphocytes, do not express antigen-specific receptors (Janeway 
et al., 2002). Nevertheless their function is to recognize and kill cells/tissues that have 
been infected by viruses or cancer cells. This mechanism of identification is associated 
to expression of MHC-class I molecules. Healthy cells express MHC-class I on their 
surface and this act prevents NK cells from killing them, but virus-infected and 
malignant cells reduce their expression, hence they will be eliminated by NK cells. 
Furthermore they produce IFN-γ (interferon-γ), a cytokine which activates macrophages 
so they can kill ingested microbes (Roitt et al., 1989). 
 
Complement system is an enzymatic system of serum proteins that are sequentially 
activated during two different pathways, the “classical” and the “alternative” pathway, 
resulting in a variety of antimicrobial defence. Complement components play a role in 
phagocytic chemotaxis, opsonization and the inflammatory response, and may be 
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involved in the lysis of certain bacteria, some viruses and other microorganisms (Roitt et 
al., 1989). 
 
 
 
1.1.2 Adaptive immunity 
 
When our first line of defence, the innate immunity, is not sufficient to protect the host 
against an invading pathogen and fails, the pathogen may yet be detected and attacked 
by the mechanisms of adaptive immunity. This second line of defence however takes 
some time to develop, as it has to accommodate to attendance of invading organism.  
 
Adaptive immune system is also called acquired or specific immune system due to the 
fact that its response is antigen-specific. This specificity is demonstrated by the cells of 
adaptive immunity when some of them express membrane receptors that are capable of 
discriminating fine differences in structure between diverse antigens (Abbas and 
Lichtman, 2003). An antigen is defined as a substance that reacts with antibody 
molecules and antigen receptors on lymphocytes (Janeway et al., 2002). They may be 
products of microorganisms as well as molecules of non-infectious nature (Abbas and 
Lichtman, 2003). Moreover, acquired immunity also distinguishes among individual’s 
own (self) and foreign (non-self) antigens, however lymphocytes that are competent of 
identifying self antigens are destroyed. This property is essential for preventing 
reactions against host’s own cells and tissues (Abbas and Lichtman, 2003). 
Another feature of acquired immunity is the immunological memory, what means that 
adaptive immune system “remembers” that it has encountered an antigen and 
consequently it responds more rapidly and more effective to subsequent exposure to the 
same antigen. Accordingly, the reaction to the prior exposure to antigen is managed by 
naïve lymphocytes, and repeated encounters with same antigen stimulate memory 
lymphocytes (Abbas and Lichtman, 2003). 
 
In this context, it is appropriate to name the components of adaptive immune system, 
these are the lymphocytes and their products, e.g. antibodies. Like innate, adaptive 
immunity also has two major branches of immune responses: the humoral and the cell-
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mediated immunity, both governed by different types of cells. Humoral immunity 
involves the secretion of antibody molecules in response to an antigen and is mediated 
by B-lymphocytes. Cell-mediated immunity involves the production of cytotoxic T-
lymphocytes and activation of certain phagocytes, and it is mediated by T-lymphocytes 
(Abbas and Lichtman, 2003). 
Both classes of cells arise from stem cells in the bone marrow, though they mature in 
different locations. Maturation of B-cells occurs in the bone marrow whereas T-cells 
develop in the thymus (Janeway et al., 2002). They differ in phenotype and function but 
can be distinguished by surface molecules they express. These are proteins and can be 
detected by monoclonal antibodies. The nomenclature for such markers uses the “CD” 
(cluster of differentiation) number designation. This system allows us to identify and 
isolate different lymphocyte populations (Abbas and Lichtman, 2003).  
 
The major function of B-cells is to recognize extracellular antigens and accordingly 
evolve and proliferate into antibody-secreting plasma cells. Antibodies are determined 
as soluble glycoprotein molecules that specifically recognize and bind to specific 
antigens that caused their production by B-cells. This act of binding initiates the process 
of activation of other cells with the mission to kill or remove the antigenic substance 
from the body (Roitt et al., 1989).  
 
T-cells are divided into two subsets that are functionally different. Firstly there are T-
helper (Th) cells, also called CD4+ T-cells, and these again are classified into Th-1 and 
Th-2 cells. Th-1 cells collaborate with mononuclear phagocytes and help them kill 
ingested pathogens whereas Th-2 cells stimulate B-lymphocytes to divide and produce 
antibodies. 
The second subset of T-cells implicates the cytotoxic, CD8+ T-lymphocytes (CTLs). 
These are involved in directly killing of virus-infected host cells or certain tumor cells 
(Roitt et al., 1989). 
 
When matured, B- and T-lymphocytes migrate to peripheral lymphoid organs and either 
stay there or return to blood-circuit via lymphatic vessels (Janeway et al., 2002). 
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The initiation of adaptive immune response requires that antigen get captured and 
presented to specific lymphocytes. The cells that carry out this function are called 
antigen-presenting cells (APCs). The most important APCs are DC, which take up the 
antigen at the site of infection and transport it to lymph nodes where naïve lymphocytes, 
cells that have not encountered any antigen before, recognize the pathogen. T cells, 
however, can detect antigens only when these are bound to host molecules expressed on 
surface of other cells called major histocompatibility complex (MHC). The stimulation 
of T-lymphocytes leads to activation of macrophages and B-cells and also causes 
launching of many other mechanisms in order to combat the infection. 
For further development of the adaptive immune reaction, activated T-cells but also 
macrophages and other leukocytes need to proliferate and differentiate into effector cells 
on one hand whose task is to eliminate the antigen, and into memory cells on the other 
hand, which are responsible for augmented responses upon repeated encounters with the 
antigen (Abbas and Lichtman, 2003). 
 
 
 
 
1.2 ALLERGIC ASTHMA 
 
 
1.2.1 General introduction to allergic asthma 
 
Allergic asthma is a chronic disease of airway inflammation and airway obstruction 
characterized by symptoms including wheezing, chest tightness, shortness of breath, 
cough and mucous hypersecretion (Epstein, 2004b). It occurs as a result of exposure to 
defined allergens initiating a cascade of cellular activation events within the lungs. The 
consequence is an inflammatory process orchestrated by a complex assortment of cells 
(inflammatory, immune and resident lung cells) and other mediators, such as cytokines 
they release (Epstein, 2004b).  
 
Observing for a longer period, airway hyperresponsiveness (AHR) and increased mucus 
hypersecretion, as well as damaged airway epithelium are some of the effects. These 
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appearances can seriously influence both, airway structure and function (Epstein, 
2004a).  
 
Inherent in the definition of asthma is the possibility of variable extent and 
manifestations of the disease between the individuals. Depend on the type of allergen 
exposure, indices can be seasonal, chronic or intermittent. Therefore, many patients 
have mild and infrequent symptoms, whereas others may have persistent or prolonged 
symptoms of great severity (Epstein, 2004b). 
 
Statistics provided by studies reveal that there are approximately 300 million people 
worldwide affected by asthma (Selgrade et al., 2006) and it is the most common chronic 
pulmonary disease among children (Asher et al., 1995; Epstein, 2004a). The disease is 
more and more representing a significant economic and social burden (Asher et al., 
1995; Epstein, 2004a; Epstein, 2004b; Selgrade et al., 2006). Rising incidence and 
prevalence are mainly reported in industrialized countries (Asher et al., 1995; Epstein, 
2004a; Selgrade et al., 2006). Here, data concerning deaths from asthma suggest a trend 
toward an increased mortality rate, this despite of improved means of prevention and 
treatment and greater availability of effective drugs (Epstein, 2004a).  
 
A number of explanations have been discussed, including the effects of certain 
medications (e.g. aspirin) (Selgrade et al., 2006), increasing exposure to industrial 
pollutants and/or indoor allergens (Asher et al., 1995; Epstein, 2004a; Selgrade et al., 
2006), overuse of β2-agonists (Epstein, 2004a), fewer viral infections during the 
childhood (Epstein, 2004a; Selgrade et al., 2006), but also limited exposure to 
microorganisms and their products in early age (Selgrade et al., 2006). 
 
Truly, remarkable progresses have been made in recent decades, however there is more 
to be done in order to clarify the cause, the mechanisms and the consequences of the 
disease.  
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1.2.2 Pathogenesis 
 
Allergic pulmonary disorder such as allergic asthma develops when an encounter with 
allergen, that normally does not have any infections or pathogenic potential, induces an 
immune response. However, it is not clear why this immunological phenomenon affects 
only some of the individuals (Epstein, 2004b). Of course, the susceptibility varies 
among different age groups and races, but genetic predisposition combined with 
geographical and cultural factors certainly have a huge impact on the prevalence of the 
disease (Selgrade et al., 2006). 
The occurrence of allergic asthma requires prior sensitization to a specific allergen. This 
incident results in the recruitment of many cells and other mediators to the location of 
the reaction, so that they are advanced to provoke a fast and strong immune response 
upon the following encounter with the antigen (Epstein, 2004b; Pearlman, 1999). 
However, once the allergen has breached the barriers and invaded the organism, it gets 
ingested and fragmented by antigen presenting cells (APC), so they can display its 
pieces on their surface to the lymphocytes (Epstein, 2004b). Provided that antigenic 
peptide is attached to MHC class II molecule on APC, then naïve T helper cells can 
react via their T cell receptor (TCR) with the antigen-MHC-II-complex, an interplay 
essential for their activation and differentiation (Pearlman, 1999). A factor that may 
influence the differentiation of Th-cells is the cytokine profile evoked by the antigen 
(Pearlman, 1999). In case of atopic asthma, T cells turn into Th-2 cells and produce 
particularly Th-2 type cytokines including IL-4, IL-5, IL-9 and IL-13 (Finotto et al., 
2000). IL-4 again favours the generation of Th-2 cells (Pearlman, 1999). Further, the 
cytokines released by Th-2 subset also affect B cells. Once more, IL-4 plays the key role 
in activating B cells and triggers their production of IgE immunoglobulins, in other 
words antibodies. B cells, however, can receive this help from T-lymphocytes, provided 
that B cells themselves have come across the specific antigen and have identified it 
(Pearlman, 1999). The synthetized immunoglobulins contain in their structure a site for 
binding an antigen. Hence, once the antigen is attached, IgE fixates to the mast cell by 
bridging its high-affinity cell surface receptor FcεRI (Epstein, 2004b). This, in turn, 
signalizes intracellular events initiating release of inflammatory mediators: histamine, 
leukotriene, platelet-activating-factor (PAF) and bradykinin (Pearlman, 1999). These 
chemicals act locally, in airway tissue that is, and are responsible for increased vascular 
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permeability, airway edema and bronchoconstriction, but also increased mucous 
secretion, all of them events that illustrate the acute-phase response (Pearlman, 1999). 
Accompanied by coughing, wheezing, and hindered breathing, the immediate response 
occurs in the first minutes after allergen encounter. Over the next 3-11 hours there is a 
progressive tissue infiltration of inflammatory and immune cells, involving eosinophils, 
neutrophils and basophils, as well as lymphocytes, in response to other chemical 
mediators. Again, particular cytokines appear to be significant for the recruitment of 
leukocytes to the site of inflammation. Not only that they draw the cells, IL-5 for 
example attracts eosinophils as well as basophils, moreover they (TNFα and IL-4) also 
enhance the number of some endothelial adhesion molecules which act as 
chemoattractants just like cytokines do (Pearlman, 1999).  
 
The contribution of leukocytes, especially eosinophils, to the extension of inflammatory 
process in the airway tissue is related to their release of cytokines and particularly 
cytolytic enzymes that very likely appear to be the main causer for tissue damage. The 
harm affects not only endothelial and epithelial cells but also nerve endings. Thus, these 
insights confirm the association of eosinophils, having a leading role in this late-phase 
response, with the clinical features in this stage of the disease, implying enhanced 
mucous secretion, airway hyperresponsiveness (AHR) (Bousquet et al., 2000; Pearlman, 
1999) and bronchial hypersensitivity (Pearlman, 1999). Long-term consequences of 
such changes and abnormalities may manifest in reversible airway obstruction and 
possible lung damage (Epstein, 2004b), however, they even can lead to death (Wardlaw 
et al., 2002). 
 
 
 
1.2.3 In vitro models of allergic disease 
 
Many studies have focussed on in vitro modelling of different diseases, and even though 
these model experiments are limited in comparison with in vivo assays due to the lack of 
various structures and microenvironment dependent processes, they still contribute to 
better understanding of cellular activities. 
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Standardized in vitro models of allergic asthma deal with cells that orchestrate 
immunological events as well as resident cells from affected tissue in the respiratory 
tract. These can be obtained directly from asthmatic patients either from blood or from 
sputum, nasal and bronchial lavages and biopsies (Epstein, 2004b; Hohenadel et al., 
2001). Bronchoalveolar lavages (BAL) are mostly utilized for identifying and 
quantification of cells and mediators present. However, for cultivation, after the 
purifying procedure, cell suspensions undergo incubation under diverse conditions. The 
analysis provides remarkable insights about their migration and secretion behaviour, cell 
proliferation, their growth and apoptosis (Epstein, 2004b). What scientists often do is to 
manipulate the cytokine environment in the cell culture in order to create a specific 
model for their experiment. An example of this was the attempt to verify that an 
increased Th-2 cytokine-induced release of certain proinflammatory mediators by 
bronchial epithelial cells from asthmatics can be amplified by direct implication of 
allergen (Lordan et al., 2002). Tests detected enhanced secretion of IL-8 and GM-CSF 
when cultures were treated solely with allergen or Th-2 cytokines (IL-4, IL-13, TNF-α). 
Yet, the combined exposure to both trigger types at the same time confirmed augmented 
expression of Th-2 cytokines in bronchial epithelium which are significant for the 
disease (Lordan et al., 2002). Another study produced a group of monoclonal antibodies 
determined as anti-CD63 and examined their effect on mast cells (Kraft et al., 2005). 
The results revealed that these antibodies suppress adhesion of mast cells to fibronectin 
and vitronectin, two specific extracellular matrix proteins (ECM), and moreover, that in 
the cells which are bound to ECM proteins anti-CD63 prevents FcεR1-initiated 
degranulation of mast cells. The project served as a basic approach for further in vivo 
assays, which evidence that anti-CD63 monoclonal antibodies potently inhibit 
anaphylactic reactions in rats. These findings suggest their potential benefit in 
therapeutical development (Kraft et al., 2005). When mentioning drug research, there, in 
vitro assays are very common. Such an example was the investigation of loteprednol 
etabonate, a soft corticosteroid with wide therapeutic index and favourable 
pharmacokinetic attributes (Szelenyi et al., 2000). In cultures with human cells 
loteprednol appeared to be capable of suppressing the secretion of various cytokines 
including TNF-α, GM-CSF, IL-4 and IL-5, demonstrating its anti-inflammatory effect in 
treating allergic responses (Szelenyi et al., 2000).  
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However, not only cell suspensions belong to in vitro models, but also biopsies can be 
arranged as explants cultures. These systems contain the required microenvironmental 
elements and enable the analysis of cellular interactions and even pathological events 
like increased mucous production or bronchoconstriction for instance (Epstein, 2004b). 
In a recent investigation, human bronchial tissue explants and human bronchial 
epithelial cells were exposed to rhinovirus and lipopolysaccharide (LPS) to test the 
mucin secretion (He et al., 2004). The findings illustrated that rhinovirus stimulated 
production of mucin in both, human bronchial tissue as well as in cell culture, and that 
the raise of the release is related to pathogen concentration. The same goes for LPS, this 
endotoxin also triggered mucin secretion in both types of ex vivo cultures (He et al., 
2004). 
 
Therefore, the data achieved by in vitro modelling is indispensable for detection and 
identification of some aspects of allergic asthma, and the insights gained are often 
fundamental prerequisite for further promising in vivo studies. 
 
 
 
1.2.4 In vivo models of allergic disease 
 
Developing in vivo models of atopic disorders has offered numerous advantages and 
progress in understanding not only the onset or initiation, the course and pathobiology 
of the disease, but it also advanced drug discovery. Due to the ethical barriers humans 
do not or hardly participate in these studies (Epstein, 2004b). Nevertheless, researchers 
have established successful animal models of the disease that are capable of replicating 
the complex biological events occurring in human patients. Monkeys, sheep, pigs, dogs, 
mice and rats are being used mostly. However, laboratories have focussed on latter two 
species, primarily for the economic reason, and secondary for their potential of genetic 
modification, and finally, for the disposability of species-specific reagents (Epstein, 
2004b; Kips et al., 2003; Torres et al., 2005). Apart from spontaneously developed 
responses, in vivo models of atopic asthma are mainly based on experimentally induced 
immunological reactions. A classic example involves intraperitoneal immunization of 
mice with chicken-egg OVA, followed by repeating intranasal challenge with nebulized 
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OVA, ending in an inflammatory state primarily ruled by T lymphocytes and airway 
hyperreactivity (AHR) (Wegmann et al., 2005). The continuous challenge induced 
elevated TGF-β levels which are associated with airway smooth muscle remodelling in 
OVA mouse objects. Moreover, the investigators also explained that manifested goblet 
cell hyperplasia and subepithelial fibrosis throughout the airway tree are related to 
chronic exposure to OVA (Wegmann et al., 2005). Other allergens used in mouse 
models of bronchial asthma are house dust mite (HDM) (Fattouh et al., 2005), 
Aspergillus fumigates (Mehlhop et al., 1997) and ragweed (Fan and Mustafa, 2006).  
 
Generally, most mouse models of asthma are featured with a Th-2 type of immune 
response implicating high levels of IgE and Th-2 cytokines such as IL-4, IL-5 and IL-
13, as well as manifested hallmarks of disease including eosinophilic lung 
inflammation, mucous hypersecretion and AHR (Epstein, 2004a). The monkey model of 
asthma exhibits similar results (Van Scott et al., 2004). In that experiment, different 
ages of probands were observed and the final outcome affirmed augmented 
responsiveness to adenosine in neonatal animals sensitized with dust mite. In addition, 
discrepancies concerning resistance in airways and dynamic compliance between adult 
and neonatal monkeys were detected too (Van Scott et al., 2004). Sheep samples seem 
to be well suited objects for asthma induction (Bischof et al., 2003). House dust mite 
sensitized sheep developed allergic response with accentuated accumulation of 
eosinophils (Bischof et al., 2003). Similar conclusions in further sheep studies followed 
(Snibson et al., 2005). Another large animal model for testing immunological reactions 
is dog (Out et al., 2002). Apparently, dogs show many asthma-like symptoms like 
eosinophilia and enhanced IgE, but also changes is respiratory tract leading to AHR 
(Redman et al., 2001). Finally, guinea pig belongs to potential representatives of 
asthmatic disease models as well (Hutson et al., 1988). However, since they lack in 
genetic diversity, they might not be used for studies as often as mice (Isenberg-Feig et 
al., 2003). 
 
All together, animal models are optimal tools for exploring pulmonary immunological 
disorders and underlying mechanisms on cellular and molecular level, and to exert the 
achieved findings in drug development (Zosky and Sly, 2007). Nevertheless, the fact is: 
animal species do not accurately replicate humans in regard to physiology and 
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pathobiology, and thus all the processes involved. Therefore, the data should be 
processed with caution (Epstein, 2004b; Zosky and Sly, 2007). 
 
 
1.3 MOUSE MODELS OF ALLERGIC ASTHMA 
 
 
1.3.1 “Mouse trap” or useful models for studying disease? 
 
The first data on mouse models with asthma-like disorder were released in 1994 
(Epstein, 2004a), and since then they have become most popular animal subjects for 
simulation and studying the disease.  
Numerous advantages have contributed to this progression, if we think of low costs they 
generate, the accessibility to mouse-specific reagents and the remarkable technologies 
allowing manipulation of their genetic background (Torres et al., 2005).  
 
As it is generally known, no laboratory animal can reproduce allergic respiratory disease 
to 100 percent as it is observed in humans. Like every other model, mice have their pros 
and cons as well. The question is whether the strengths or their weaknesses prevail, in 
other words: Are mice valuable models for the disease?  
 
Since animals do not develop allergic asthma naturally, with some exceptions like T-bet 
transcription factor-deficient mice (Finotto et al., 2002), or flea-allergic dogs (Epstein, 
2004b), asthmatic conditions have to be induced in a model. There is a variety in 
techniques scientists apply, but in principle the standardized OVA protocol is the most 
commonly used (Torres et al., 2005; Zosky and Sly, 2007). This method includes 
sensitizing mice systemically, either through intraperitoneal (i.p.) injection with antigen 
and an adjuvant added, or immunization with allergen via intranasal/intratracheal routes 
(Epstein, 2004a; Zosky and Sly, 2007). The systemic priming and subsequent challenges 
with the antigen lead to immune response in the respiratory tract hallmarked with lung 
inflammation, airway hyperresponsiveness, mucus hyperproduction, edema, abundant 
eosinophils and enhanced IgE levels, respectively (Epstein, 2004a). 
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However, the protocols also undergo modifications. As our knowledge about mice and 
disease grows, consequently, more questions arise and this is being reflected in the 
disease induction strategies.  
 
Which allergen to choose? Well, as mentioned, the most frequently used is OVA. 
However, there have been made studies with a number of other allergens including 
bovine serum albumin, Aspergillus fumigatus, cockroach antigens, birch, as well as 
ragweed extracts and house dust mite (HDM) (Epstein, 2004a). Especially the latter two 
stimuli are increasing in popularity, due to the fact they are natural allergens dispersed 
in the air and capable of eliciting hypersensitivity reactions in humans. Naturally, they 
invade the organism through respiratory passages, whereas OVA is ingested by 
gastrointestinal tract, suggesting that immune reaction evoked should commence in our 
intestines (Torres et al., 2005), nevertheless it has not been evidenced yet that priming in 
individuals takes place in the respiratory tract when inhaling the allergen (Epstein, 
2004a). 
 
On the other hand, diverse experimental methods imply diverse application rates. 
Basically, standardized protocols dictate high concentrations of OVA. Unlike house dust 
mites, in terms of this allergen low doses are required for techniques targeting mouse 
models with chronic asthma (Torres et al., 2005). 
  
For the sensitization, antigens are administered not only in a soluble form but often 
precipitated in aluminium sulfate (alum), an adjuvant, with the intention to provoke 
augmentation in Th-2 guided bronchial response. Referring to humans, substances like 
cigarette smoke, ozone or exhaust fumes for instance, function as adjuvants for atopic 
diseases of respiratory system (Epstein, 2004a). 
 
Divergent reactions have also been observed among certain mouse strains (Kannan and 
Deshpande, 2003). Although some researchers regard it as a handicap, discrepancies 
like these provide a basis for investigating the association between genetic make-up and 
the pathological events (Shapiro, 2006). Primed BALB/c mice appear to suffer from 
stronger airway hypersensitivity accompanied with higher levels of IgE and cytokines, 
compared with primed C57BL/6 strain. Contrarily, A/J mice seem to be more adequate 
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for developing a chronic condition that is believed to be more like the asthma occurring 
in humans (Torres et al., 2005).  
With this in mind, scientists are making further changes in the immunization protocols. 
Instead of the usual i.p. antigen injection, they wage new trials recommending not 
systemic but priming via respiratory routes and the same way for the following 
challenges (Torres et al., 2005). 
 
Similar thoughts apply to the length of the initiation experiment. Here, basically, a 
distinction is drawn between brief exposure to high dosed allergen and, conversely, 
protocols with extended period of exposure using low concentrations of antigen. 
Evidence shows that first technique, i.e. short exposure, ends in an acute model of 
allergic asthma (Torres et al., 2005). 
 
To study the acute disease in mice, numerous technologies have been developed. 
Airway inflammation, for example, is assessed with BAL (bronchoalveolar lavage), and 
it is determined that cells with the greatest abundance are eosinophils, followed by 
neutrophils and macrophages. In this context it is necessary to note that eosinophils are 
a contentious issue regarding mice and men (Epstein, 2004a). Firstly, in contrast to 
humans, eosinophils in mouse models do not degranulate, hence this controversy is 
sometimes seen as a serious limitation for mouse subjects (Persson, 2002). The second 
point of contention affects their function. There are views proposing that eosinophils 
may be implicated primarily in regulatory operations rather than promoting the 
inflammation process (Torres et al., 2005). 
 
Concerning the antigen-specific IgE and mast cells, here, opinions differ again. 
Asthmatic patients have demonstrated their essential role in the development of early- 
and late-phase-response as well. In mice, assays have exhibited that the initiation and 
gravity of the asthma onset do not depend on IgE or mast cells. On the other hand, in 
many investigations the opposite has been proved confirming the relevance of these two 
players for the disease in mouse systems (Epstein, 2004a). Genetic distinction (Epstein, 
2004a), just as varying induction protocols (Torres et al., 2005) could substantiate these 
discrepancies. 
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Another feature of atopic asthma is the airway hyperreactivity. Noninvasive and 
invasive methods are being applied to evaluate this disorder, but laboratories prefer the 
noninvasive proceeding. The most commonly used is the so-called whole body 
plethysmography (WBP), a technique comprising stimulation of mice with either 
allergenic or cholinergic bronchoconstrictors and measuring the following reactivity of 
the airways (Epstein, 2004a; Kumar and Foster, 2001; Torres et al., 2005). During such 
operations researchers have encountered another phenomenon that argues against mice, 
unfortunately. The stimulant metacholine evokes hyperreactivity in human individuals 
even when the symptomatic condition alleviates, whereas mouse models demonstrate 
only temporary hyperresponsiveness during the immunization and challenge phases, an 
occurrence based on anatomical and physiological distinctions between the two species 
(Epstein, 2004a). 
 
One of the main weaknesses of most mouse models is the deficiency of chronicity that 
is ascertained in asthmatic patients. In order to generate conditions that are closer to 
those in humans, induction protocols had to be altered in certain aspects. When testing 
novel pathways of initiation, investigators acquired significant and interesting findings, 
namely, if mice are exposured to OVA for longer time with no preceded systemic 
sensitization, they will develop immunologic tolerance. In other words, the immune 
response will be suppressed (Torres et al., 2005). It is most likely this incident is related 
to defence mechanisms of the immune system and supplied the foundation for the 
allergen immunotherapy (Epstein, 2004a). Similar events were illustrated in primed 
models after extended exposure to OVA, bronchial inflammation was relieved. The data 
was encouraging, thus in addition to prolonged exposure, decreased allergen 
concentration established in protocols as well. In a recent study, a mouse model was 
designed in accordance with those new instructions. House dust mite antigen was used 
and the outcome of the experiment was a model of chronic disease with manifestation of 
airway remodelling, a state more typical for allergic asthma in patients (Torres et al., 
2005). 
 
Altogether, mouse models of asthma are useful tools for identifying and testing 
mechanisms underlying allergic pulmonary disorders. 
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No question, there are limitations in mouse systems that need to be considered when 
estimating their suitability, adopting and adjusting the data achieved to humans. 
Differences in physiology, disputed significance of IgE and mast cells for the response 
development in mice and men, these are only few of arguments against mice. 
Furthermore, age of animal subjects is often being criticized. Indeed, modelling is 
mainly performed in adult animals, whose immune system compared to the young or 
neonates actually is sophisticated and acts more effectively in combat against pathogens 
and diseases (Kips et al., 2003; Selgrade et al., 2006). Hence, it surely would be 
interesting to create a model that, as a neonate and juvenile has been set out to early life 
influences typical for men including viral infections and environmental factors (i.e. air 
pollution, natural indoor and outdoor allergens, microorganisms and their products etc.), 
and observe to what extent these elements play a role in asthma development at various 
time points (from early age to adults).  
Another problem with mice when compared to asthmatic patients is the temporary AHR 
to bronchoconstrictive agents (Epstein, 2004a).  
 
Nevertheless, it is primarily mouse who brought the science to where it is now. These 
small animals provided needful understanding for pathogenesis and notable findings for 
the therapeutical field. 
Of course, many issues demand to be elaborated before starting an experimental 
induction, reaching from the choice of allergen to mouse strain, but it mainly depends 
on the target of modelling or the hypothesis that needs to be verified (Torres et al., 
2005). Consequently, it is important to combine the investigations in both, mice and 
men, so that the insights gained in animals can be tested in humans. 
 
No doubt, mice are and will remain useful and appropriate means for further research of 
allergic lung disease.  
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 1.3.2  Sensitization to allergen 
 
To induce allergic reaction in the respiratory system in mice, animals primarily need to 
undergo a systemic immunization. In the most of prevalent models, mice are sensitized 
by the intraperitoneal injection of OVA allergen either in combination with adjuvant 
alum, or in adjuvant-free solubilized state (Epstein, 2004a; Zosky and Sly, 2007). 
Furthermore, intranasal or intratracheal instillation of particular allergens, as well as i.p. 
or intratracheal transfer of primed DCs and macrophages have been proved as 
successful methods for sensitization process (Epstein, 2004a). Immunizing the mice 
systemically causes activation of their immune system including production of antigen-
specific IgE (Kips et al., 2003), and actually provides a base for disease to be initiated 
and developed by following inhalation of allergen (Epstein, 2004a), an insight gained 
from models who revealed that asthmatic events featured with increased IgE secretion 
(Holt et al., 1981; Seymour et al., 1998) as well as the predominantly Th-2-ruled 
response (Seymour et al., 1998) do not occur upon repeated inhalative challenges alone. 
This was further encouraged by a demonstration in unsensitized mice, who after being 
loaded with antigen-stimulated Th-2 cells from OVA-primed wild-type mice, became 
exposed to aerosolized OVA and, as a result, recipient mice developed allergic 
pulmonary response (Hogan et al., 1998). 
 
Hence, systemic priming creates a generation of activated Th-2 cells, which are the key 
players in setting a stage for immunological allergic reactions upon subsequent airway 
challenges in mouse models.     
 
 
 
1.3.3  Factors influencing the response to allergen 
 
A number of elements involved in asthma induction in mice are able to manipulate the 
procedure and lead to discrepant achievements.  
 
Adjuvants are substances that enhance Th-2-ruled immunological reaction. This trait 
was evidenced with many essays, in which adjuvant was administered systemically with 
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no antigen added and as a consequence a non-specific Th-2 cytokines generation 
eventuated (Epstein, 2004a). Analog the allergen effect, applying the allergenic 
substances alone in the sensitization phase causes a Th-2 phenotype of asthma (Epstein, 
2004a). To conclude, initiation of the disease does not need addition of an adjuvant to 
antigen. Another assay fortified these findings regarding the adjuvants function, when 
compared the phenotype of infiltrates in inflamed lungs of mice, which previously were 
sensitized either with antigen precipitated in alum or immunized with OVA alone. 
Results demonstrated that infiltrates correlated to combination of antigen and adjuvant 
were bigger and were settled close to large airways with eosinophils in abundance, in 
opposite to infiltrates related to soluble OVA, those appeared smaller, harboured fewer 
eosinophils and were found mainly near smaller airways, resembling rather the nature of 
human cellular infiltrates (Epstein, 2004a). 
 
Apart from the most popular adjuvant aluminium sulfate (alum), there are various others 
that participate in such experiments. Some of them, however, appear to be absolutely 
necessary for development of the disease. Since it is verified that bacterial LPS 
(lipopolysaccharides) are present in OVA protein, researchers also wanted to explore the 
effect of this endotoxin, therefore they segregated it from OVA and conducted the 
induction in a mouse model with the purified OVA. The outcome illustrated alleviation 
of asthmatic state, alluding to the relevance of LPS for priming the immune system 
(Epstein, 2004a). On the other hand, a controversial study showed that applying LPS to 
mice during the nebulization with aerosolized antigen leads to degradation of the 
immune response. These discrepant findings may be due to differing administration 
routes of endotoxin, nevertheless it is not clarified yet (Epstein, 2004a).  
 
Fortunately, there are factors that suppress asthma induction as well, even though some 
of them have pathogenic character. Parallel ongoing infections, Mycoplasma 
pneumoniae for instance, seem to decrease the allergic reaction. With this evidence the 
corroboration for hygiene hypothesis grows and further affirms that in industrialized 
countries where advanced hygiene circumstances and minor infectious impacts are 
ubiquitous, these conditions just increase the susceptibility for allergic diseases 
including asthma (Epstein, 2004a; Selgrade et al., 2006).  
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Then again it is the experimental protocol implying other influencing factors beside the 
adjuvants. Mouse strain can determine whether the response will turn out milder or 
stronger.  
The choice of allergen is also important, currently, the laboratories incline to use natural 
aeroallergens that are responsible for human asthmatic events, i.e. house dust mite.  
 
Not to forget, the route of exposure as well as duration are the central issues in the 
sensitization process in mouse models by far. Brief exposures with high amount of 
antigen are appropriate for acute onset of the disease in mice, whereas chronic models 
are related to extended challenges with low allergen concentrations. Regarding the route 
of administration, on the one hand, scientists recommend both steps to be executed via 
respiratory ways, priming just as challenges, with the argument that this is the natural 
way how humans encounter antigens (Torres et al., 2005). On the other hand, it is not 
verified whether individuals are truly primed via airways (Epstein, 2004a). This may be 
supported by mice who demonstrated that asthma induction requires systemic priming 
and subsequent respiratory challenges. In other words, if mice are only nebulized for a 
long time and had no prior systemic administration of allergen, after a while they 
develop immune tolerance. Now, what about the immune tolerance and humans with 
chronic state? One possible explanation claims that this protective mechanism 
underlying the defence system in individuals is impaired (Torres et al., 2005). Other 
option suggests that, if humans successfully generate immune tolerance to inhaled 
allergens, then susceptible persons among will develop immune response in case of 
being primed systemically (Epstein, 2004a). 
 
Last but not least, allergenicity plays role in the immunization course (Epstein, 2004a), 
although the importance in mouse systems differs from the importance for disease in 
men. 
Since the allergenicity is explicated as the innate potential of a protein to elicit 
hypersensitivity, and since mice effectively respond to antigens of non-allergenic 
character, it is clear that disease induction in mice does not require allergenicity. Atopic 
individuals, however, have in common that they generate an immunological response to 
a group of certain antigens, thus obviously the allergenic nature is requested for 
sensitization in humans (Epstein, 2004a).  
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Altogether, we realize that in the priming phase everything is interconnected. 
Depending on the aim of the study, these influences need to be deliberated in advance, 
and accordingly either incorporated or eliminated.  
 
 
 
1.3.4  Acute and chronic disease in mouse models 
 
Mouse models are necessary to study and understand the mechanisms of allergic disease 
and for this purpose they enable manipulation of incidents of the disease. Therefore it is 
possible to compile a chronology of asthmatic pathology and to distinguish between 
acute inflammation and chronicity of asthmatic disorders.  
 
Considering the lung physiological and immunological aspects, mouse system offers 
numerous advantages such as valuable techniques for investigating the immuno-
pathological correlations in allergic asthma. The model of acute inflammation of 
airways, initiated through repeated short-time inhalative allergen exposure, has become 
established many years ago (Zosky and Sly, 2007). This form of immune response is 
manifested with coughing, wheezing, shortness of breath and dyspnea (Bousquet et al., 
2000; Epstein, 2004a). On the cellular and molecular level it is characterized by lung 
inflammation, mucus hypersecretion, airway hyperresponsiveness and increased IgE 
production (Bousquet et al., 2000; Epstein, 2004a; Kumar and Foster, 2001; Torres et 
al., 2005). Mouse models are valuable in so far as they allow measurement and 
evaluation of these events. Lung inflammation for example can be assessed on the basis 
of BAL and histopathology (Epstein, 2004a; Torres et al., 2005). The analysis of BAL 
fluid provides indication on cell recruitment in the airways (Epstein, 2004a; Hohenadel 
et al., 2001; Tobin, 2001), including eosinophils, lymphocytes, monocytes and 
neutrophils (Bousquet et al., 2000; Epstein, 2004a). The insights gained from BAL are 
mainly consistent with the histological examination of lungs proposing that the 
inflammation is primarily eosinophilic, peaks during 24 to 48 hours after last challenge, 
and declines after 11 days (Epstein, 2004a; Kung et al., 1994). Furthermore, the analysis 
proves that inflammation is constricted to perivascular and peribronchial regions in the 
lung (Epstein, 2004a; Kung et al., 1994). Bronchial hyperresponsiveness can be 
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measured by invasive and non-invasive methods. The most frequently used is the non-
invasive whole body plethysmography technique that measures AHR in mice in 
response to bronchoconstricting/allergenic agents (Epstein, 2004a; Kumar and Foster, 
2001; Torres et al., 2005). The levels of IgE or IgG can be assessed using ELISA (Coyle 
et al., 1996). Unlike IgG level, the amounts of IgE are proved to diminish in a period of 
few months (Epstein, 2004a). Mucous cell hyperplasia as a feature of acute 
inflammatory reaction is accompanied by mucous hyperproduction, and these structural 
changes can be evidenced by histological staining of lung sections with PAS (periodic 
acid-Schiff) (Epstein, 2004a).  
 
Designing a mouse model with chronic disease is a movement towards replication of 
asthmatic conditions in humans. The attempts to create such conditions with OVA 
antigen in mice failed. Continuous and prolonged respiratory exposure to OVA rather 
causes immunological tolerance (Johnson et al., 2004; Torres et al., 2005). In contrast, 
chronic provocation with house dust mite extract induces severe eosinophilic 
inflammation with raised levels of IgE and IgG as well as enhanced production of Th-2 
type cytokines (Johnson et al., 2004). Moreover, airway remodelling, that belongs to 
major hallmarks of chronic allergic asthma, has been evidenced in such models. Airway 
remodelling is described as a result of consecutive repair processes of continuously 
injured structures in lungs (Bousquet et al., 2000; Epstein, 2004a). It is associated with 
subepithelial fibrosis, hypertrophy of bronchial smooth muscle, hyperplasia of goblet 
cells and mucous hyperproduction, along with microvascular deformation (Bousquet et 
al., 2000; Epstein, 2004a; Johnson et al., 2004; Torres et al., 2005). These changes 
contribute to enhanced airway obstruction and consequently, to growing respiratory 
resistance (Bousquet et al., 2000). Additionally, increased AHR is also noted in chronic 
models. Different from acute disease, chronic subjects demonstrate fewer eosinophils in 
infiltrates (Epstein, 2004a), but greater numbers of macrophages, plasma cells and T 
lymphocytes (Epstein, 2004a; Johnson et al., 2004). However, the lung inflammation is 
reported to resolve completely after few weeks of continuous exposure to antigen, 
whereas AHR and immunoglobulins remain increased (Epstein, 2004a; Johnson et al., 
2004). Apart from that, structural changes stay persistent (Johnson et al., 2004).  
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In summary, both, acute and chronic form of allergic pulmonary disorder can be 
investigated in mice. Acute disease models are suitable for exploring the inflammation 
process and underlying mechanisms, whereas mouse systems with chronic conditions 
can be employed for studying the long-term processes and effects on lung function due 
to tissue damage and structural abnormalities. 
 
 
 
1.4 Th-2 MEMORY 
 
Immunological memory is a relevant attribute of immune responses. After a 
disease/infection has been abolished and the invading agents eliminated, an increased 
number of specific immune cells remain in the body and they serve to protect the host 
against re-infection. A secondary encounter with the identical pathogen stimulates these 
long-lasting memory cells, which elicit more rapid and enhanced immune reaction than 
to the first exposure (Goldsby et al., 2001). The exact process by which immunological 
memory develops is not thoroughly explored. To date, proposals for the advantages 
which might drive the evolution of memory include: protection from re-infection, 
control of long-term infections, and the heredity transmission of immunity to the next 
generation (Welsh et al., 2004; Wodarz, 2003). However, memory does not always and 
exclusively stand for host protection, but it can promote disease relapse and extension as 
well. The significance of Th-2 lymphocytes for induction and evolution of allergic 
asthma has often been highlighted in experiments (Bell et al., 1996). Deactivating Th-2 
cells or their cytokines results in reduction of asthmatic symptoms (Bell et al., 1996; 
Epstein, 2006; Mojtabavi et al., 2002), and adoptive transfer of allergen-specific Th-2 
population to naïve animals leads to disease development (Epstein, 2006; Mojtabavi et 
al., 2002). No doubt, an existent frequency of Th-2 memory cells is required by 
immunological memory (Bell et al., 1996; Epstein, 2006; Mojtabavi et al., 2002). A 
valuable study supporting this perception verified the persistence of Th-2 memory cells 
in a murine model of allergic asthma (Mojtabavi et al., 2002). Their sensitization 
protocol involved immunization with soluble, nebulized and not precipitated OVA 
antigen in order to prevent adjuvant-dependent antigen deposits in the body. After the 
efficiently induced asthmatic inflammation, mice rested for extended periods of time to 
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be able to entirely recover from clinical symptoms. More than 1 year later, mice were 
again challenged with aerosolized OVA and as a result they restored inflammatory 
events in lungs characterized with eosinophilia, inflammatory infiltrates containing large 
amounts of eosinophils followed by lymphocytes and macrophages, AHR, mucous 
hyperproduction and generation of IgE. Furthermore, recovered animals proved to react 
rapidly against OVA re-exposure by producing Th-2 cytokine RNA in lungs only 3 
hours after the antigen stimulation, suggesting the longevity and promptness of Th-2 
cells in lungs. To compare, recovered control mice, which did not undergo rechallenge 
process after 1 year, evidenced long lasting lymphocytic infiltrates without eosinophils, 
and no other asthma-like features such as AHR, eosinophilic inflammation or increased 
mucous production. Except in lungs, persistent memory Th-2 population was detected in 
spleen as well. Beside the rechallenged animals, also spleen isolated cells from 
recuperated mice exhibited in vitro IL-4 and IL-5 secretion upon antigen stimulation. 
All in all, findings from this study demonstrate the persistence of Th-2 memory cell 
population in spleen and lungs that initiates rapid immune response upon second antigen 
encounter leading to evolution of allergic asthma (Mojtabavi et al., 2002). On the one 
hand, there is evidence that memory is based on long lasting CD4+ T cells in lung 
infiltrates proposing that lungs participate in maintaining of Th-2 memory by providing 
an ambience favourable for survival of memory cells (Epstein, 2004a). On the other 
hand, to date, it is unclear whether antigen deposits allowing the continuous availability 
and Ag presentation is involved in the process of memory maintenance and/or to what 
extent. Although in the assay previously described Ag deposits were prevented, there 
was no guarantee that during the recovery phase inhaled OVA was eliminated to 100% 
and that some irreducible minimum of Ag does not remain in respiratory system and 
support the perpetuation of memory (Mojtabavi et al., 2002). Indeed, researchers have 
documented that T cell memory is antigen dependent (Kündig et al., 1996). However, 
some experiments reveal that memory T cells do not require persistent antigen for their 
survival (Murali-Krishna et al., 1999). Though, they proved the competence of these 
memory cells to respond to antigen re-exposure with generation of cytokine profile 
needed for asthmatic reaction. Furthermore, Murali-Krishna et al. indicated that memory 
CD8 T cell subset is capable of lasting and proliferating without presence of MHC class 
I molecules. Thus, antigen persistence stays a debatable issue that demands deeper 
investigation. In addition, cytokines have also been targets of projects in order to verify 
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their contribution to sustain T cell memory. According to certain studies, in particular 
IL-7 (Schluns and Lefrançois, 2003) and IL-15 (Berard et al., 2003; Schluns and 
Lefrançois, 2003) appear to play a role in that process.  
 
All together, great amount of inconsistent data has been presented and gives rise to a 
myriad of questions concerning T cell memory and its maintenance that need to be 
clarified. 
 
 
 
1.5 DC AND ALLERGIC ASTHMA 
 
DC are bone-marrow derived and highly migratory cells of immune system that belong 
to antigen-presenting cells (Goldsby et al., 2001). Their main function is to capture 
antigens, metabolize and present it to T cells in lymphoid organs. To date, their central 
role in initiation and enhancement of pulmonary immune responses to antigens has been 
revealed by numerous studies. They appear to have the ability to determine the nature of 
immune reaction to Ag encounter, which can be either inflammatory or tolerogenic. 
Furthermore, they seem to possess the qualification to direct the immune response either 
towards Th-1 or Th-2 pattern (Kuipers and Lambrecht, 2004; Lambrecht, 2005; Upham 
and Stumbles, 2003).  
 
To be able to present the Ag and activate naïve T cells followed by initiation of immune 
response, DCs need to undergo their maturation process. Immature DCs are spread 
throughout lungs and many of them are situated beyond and beneath the respiratory 
epithelium, the front line of host defence (Lambrecht, 2005). By Ag uptake, DCs 
migrate with their Ag-load to regional lymph nodes (Lambrecht, 2005; Upham and 
Stumbles, 2003). They reach the lymph nodes within first 12h (Lambrecht, 2005). When 
arrived, DCs express Major Histocompatibility Complex Class II (MHC II) molecules 
and secrete co-stimulatory molecules including CD86 and CD40, what alludes to their 
partially mature state (Kuipers and Lambrecht, 2004). However, DCs sometimes need 
some support for their activation and migration. This support involves signals from 
Pattern-Recognition-Receptors (PRRs) after Pathogen-Associated-Molecular-Patterns 
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(PAMPs) have bound to them (Eisenbarth et al., 2003; Kuipers and Lambrecht, 2004). 
Additionally, there are certain chemokines, like CCL21 for instance, and many other 
poorly explored mechanisms that mediate DC activation and migration as well (Upham 
and Stumbles, 2003). Once they have processed the ingested Ag, DCs transport its 
particles to the cell surface where they build a complex with MHC II molecules, and in 
this form the antigenic material is presented to T cells. This presentation leads to T cell 
activation and differentiation from naïve into effector T cells that yet proliferate and 
initiate the development of immune response (Epstein, 2004b). Interestingly, 
spontaneously migrating DCs have also been observed although in healthy individuals 
(Upham and Stumbles, 2003). By the arrival to lymph nodes they, however, remained 
immature, suggesting their potential role in immune tolerance (Kuipers and Lambrecht, 
2004; Upham and Stumbles, 2003). Apart from that, there is a report about a subset of 
DCs that store the Ag for a longer period of time in lung tissue and probably, maintain 
the ability of Ag presentation (Julia et al., 2002). 
The density of DCs in the lung depends on the magnitude of antigen provocation and 
can be elevated due to bacterial and viral infections, cigarette smoke, but also in 
response to IFN-γ (Upham and Stumbles, 2003). Indeed, investigations have proved 
increased amounts of pulmonary DCs and bone-marrow derived precursors in rodents 
with allergic asthma (Lambrecht, 2005). The number of myeloid DCs in mucosal tissue 
and BALF reaches the 80-fold higher amounts as a consequence to disease induction. 
These DCs that are recruited to inflamed lungs are often found in infiltrates together 
with primed T cells, demonstrating the interplay among these two cell types, that 
potentially leads to local maturation of DCs in the periphery in addition to lymphoid T 
cell areas (Lambrecht, 2005). This notion of their correlation and interaction is further 
supported by the fact that airway DCs secrete chemokines such as CCL17 that draw 
memory Th-2 cells to the site of inflammation (Lambrecht, 2005). Together with results 
from other experiments including the report on lung DCs that long after antigen 
inhalation these cells evidence the capability to activate T cells (Julia et al., 2002), these 
findings underscore the participation of DCs in maintaining the established 
inflammation of respiratory system (Lambrecht and Hammad, 2003; Kuipers and 
Lambrecht, 2004; Upham and Stumbles, 2003; van Rijt et al., 2005). Lambrecht and co-
workers have further substantiated this perception. Their study revealed that selective 
depletion of CD11c+ airway DCs in mouse objects completely abolished all major 
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features of asthma with Th-2 phenotype, including eosinophilic inflammation, goblet 
cell hyperplasia and BHR (Kuipers and Lambrecht, 2004; Lambrecht and Hammad, 
2003; van Rijt et al., 2005). Accordingly, transfer of DCs efficiently restored the 
pathobiological events of asthma in those animals (Lambrecht and Hammad, 2003; van 
Rijt et al., 2005). In addition, they also confirmed that removal of these DCs from 
immunized mice being subsequently challenged with Ag prevents the initiation of 
allergic inflammatory response (van Rijt et al., 2005). 
Hence, it is obvious that DCs play a pivotal and essential role in development of Th-2 
sensitization to inhaled allergens as well as in maintenance of ongoing pulmonary 
allergic inflammation. 
 
Various subsets of DC stand for various functions and locations. Basically, it has to be 
distinguished between myeloid and plasmacytoid DC, and Langerhans cells (LC) 
(Upham and Stumbles, 2003). Myeloid DC (mDC) arise from monocyte lineage that is 
in common with macrophages, circulate in blood and their survival is granulocyte-
macrophage colony stimulating factor (GM-CSF) dependent. Plasmacytoid DC (pDC) 
are found in blood stream as well, although in lower amounts than mDC, and further 
they have been identified in tissues. For their maintenance, pDC require IL-13 cytokine. 
pDCs are believed to participate in combat against viral infections (Upham and 
Stumbles, 2003). Finally, Langerhans cells are a subtype of DC located in epithelial 
tissue, particularly confined to epidermis. Their development demands TGF-β. Differing 
subsets are suspected to mediate the immune response in a different way. In this context, 
however, the results are conflicting. In humans, myeloid DCs seem to initiate a Th-1 
response that is IL-12 dependent, whereas plasmacytoid DCs appear capable of eliciting 
a Th-2 type of response (Upham and Stumbles, 2003). Contrarily, experiments with 
mice reveal that administration of OVA-pulsed myeloid DCs to the airways of naïve 
mice causes sensitization to OVA, that after rechallenging mice with aerosolized OVA 
results in a Th-2 type of immune reaction with all typical hallmarks of allergic asthma, 
including eosinophilic inflammation, goblet cell hyperplasia and AHR (Lambrecht, 
2005). These data suggest on the one hand the possible existence of two different 
subpopulations of myeloid DC, and on the other hand that these discrepancies demand 
further exploration. Nevertheless, there are some other factors proposed to influence the 
polarization of immune response. IL-12 for example, is the crucial cytokine in 
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promoting Th-1 ruled responses (Eisenbarth et al., 2003; Upham and Stumbles, 2003). 
Further, IL-10 is able to suppress production of IL-12 and therefore Th-1 differentiation, 
hence it rather contributes to Th-2 phenotype. In addition, microbial stimuli, such as 
lipopolysaccharide (LPS) (Upham and Stumbles, 2003), also showed competence to 
switch between Th-1 and Th-2 profile (Eisenbarth et al., 2003; Upham and Stumbles, 
2003). Actually, the dose of LPS was observed to manipulate the Th-1/Th-2 variation 
(Upham and Stumbles, 2003). This finding was further supported by other studies 
indicating that low concentration of Ag promotes Th-2 cell differentiation, whereas high 
Ag doses advantage Th-1 controlled immune responses (Upham and Stumbles, 2003). 
Taken together, all these findings point at one, that DC can influence the Th-1/Th-2 
balance, and that underlying mechanisms are yet not fully understood.  
 
As mentioned before, DCs not only participate in evolution of immunological 
responses, but they also play a role in the process of immune tolerance. One of the 
potent drivers that can affect their tolerogenic function is for instance TGF-β. This 
cytokine is capable of suppressing the maturation of DC, thus DC remain unable to 
stimulate T cells (Demeure et al., 2000). IL-10 has been described as another important 
cytokine for tolerance. It has been documented that pulmonary DC expressing IL-10 can 
induce foundation of regulatory T cells (Tregs) which then secrete IL-10 themselves and 
are able to suppress evolution of Th-2 responses and inflammation of lungs (Kuipers 
and Lambrecht, 2004; Lambrecht, 2005; Upham and Stumbles, 2003). Indeed, in 
opposite to allergic patients scientists have detected enhanced levels of Ag-specific IL-
10 secreting cells in healthy individuals (Kuipers and Lambrecht, 2004). Beside the 
respiratory tract DCs, a particular subset of DCs is thought to induce Tregs as well, 
namely plasmacytoid DCs. Although ex vivo, lung pDCs have shown the capability to 
induce Tregs generation and moreover to suppress formation of Th-2 effector cells that 
is stimulated by myeloid DCs (Kuipers and Lambrecht, 2004; Lambrecht, 2005). Apart 
from that, researchers have also examined the effect of different maturation states of DC 
on tolerogenic process and came to disparate outcome. While one group ascertained that 
intermediate maturation stadium was essential for tolerogenic pathway, the others 
showed that exclusively immature DC are responsible for launching the tolerance 
(Kuipers and Lambrecht, 2004). These data provide very confident results in terms of 
significance of Tregs induced by DCs, however, concerning the DC maturation stages, 
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more has to be done to clarify different states from immature toward mature and their 
impact on immune tolerance.  
 
 
 
1.6   MACROPHAGES IN IMMUNE RESPONSE 
 
Apart from DC and B lymphocytes, the population of macrophages exerts the function 
of antigen presenting cells as well. Macrophages stem from circulating monocytes, 
whose precursors promonocytes origin from bone-marrow (Goldsby et al., 2001). 
Generally, these immune cells are distributed through alveolar spaces and conducting 
airways (Peters-Golden, 2004), but in specific, they are divided in three subtypes due to 
their exact localization including alveolar, interstitial and intravascular macrophages 
(Lohmann-Matthes et al., 1994). Among these, alveolar macrophages are the only being 
in contact with air, as they are placed in the air-tissue interface. Their task is to protect 
the host against invading agents applying the mechanism called phagocytosis (Goldsby 
et al., 2001). It is described as ingestion and degradation of pathogenic and/or non-
pathogenic material of exogenous or endogenous nature (Goldsby et al., 2001). Cell 
counts in healthy animals reveal the abundance of alveolar macrophages claiming that 
they make up over 90% of cells from BAL fluid (Lohmann-Matthes et al., 1994). 
Actually, macrophages represent the largest population among immune cells in 
respiratory tract (Peters-Golden, 2004). Phagocytic activity as well as production of 
cytokines are stronger evident in alveolar macrophages, whereas interstitial 
representatives display higher expression of MHC II molecules (Lohmann-Matthes et 
al., 1994). In addition, there are further molecules that macrophages express on their cell 
surface implying CD11a, CD11b, CD11c (Lohmann-Matthes et al., 1994), CD4, CD14 
and CD40 (Goldsby et al., 2001), but F4/80 has also been identified as a macrophage 
marker (Gonzalez-Juarrero et al., 2003; Morris et al., 1991). According to their 
high/low/intermediate expression of these surface molecules what is correlated with 
their current differentiation stage and function, distinct subtypes of macrophages can be 
distinguished, however some of them are expressed by other APCs like DCs as well 
(Lohmann-Matthes et al., 1994). Alveolar macrophages are involved in both, innate as 
well as in adaptive immunity (Lohmann-Matthes et al., 1994; Peters-Golden, 2004). 
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Their support of innate immunity is demonstrated by their anti-microbial effects 
(Jansen, 1996; Lohmann-Matthes et al., 1994; Peters-Golden, 2004). The role in 
adaptive immune responses has, however, suppressive character (Jansen, 1996; 
Lambrecht and Hammad, 2003; Lohmann-Matthes et al., 1994; Peters-Golden, 2004). 
Despite the production of MHC II, macrophages are rather inadequate antigen 
presenting cells and only DCs are known to present the antigen to naive T cells (Jansen, 
1996). In this context, macrophages can show their immunosuppressive effect. They are 
capable of inhibiting the APC capacity of DCs, and thus T cell activation declines 
(Jansen, 1996). This downregulatory behaviour was demonstrated in several studies. 
One of them proved that removal of alveolar macrophages before Ag stimulation leads 
to augmented Ag-induced immune response with manifested AHR and eosinophilia as 
well as decreased amount of IFN-γ, a Th-1 cytokine that is also secreted by 
macrophages (Tang et al., 2001). These observations indicate their capability of 
initiating a protective Th1 type of response (Lambrecht and Hammad, 2003; Peters-
Golden, 2004; Tang et al., 2001). Not surprisingly, in contrast to DC, macrophages 
failed to reconstitute asthmatic conditions in mice that after elimination of DCs and 
macrophages were relieved from main features of asthma (van Rijt et al., 2005). 
Therefore, macrophages operate in two different ways to downregulate allergic 
reactions, either directly or indirectly. On the one hand they suppress DCs function and 
consequently T cell activation, thus immune response is indirectly prevented or limited 
(Peters-Golden, 2004). On the other hand, they direct immunological response towards 
Th1 phenotype (Lambrecht and Hammad, 2003; Peters-Golden, 2004; Tang et al., 
2001). In this regard, it is believed that Th1/Th2 polarization occurs due to distinct 
subclasses of macrophages distinguished by their cytokine profile and products, thus M1 
is described as promoter of Th1 response, and M2 in turn contributes to Th2 immunity 
(Peters-Golden, 2004). According to these data, macrophages have antipodial functions, 
they exhibit pro- as well as anti-inflammatory effects. The immune-regulatory and/or -
modulatory cytokines they secrete include IL-1, IL-6, IL-10, IL-12, IL-18, and further 
they produce TNF-α, IFN-γ, TGF-β as well as CSFs (Lohmann-Matthes et al., 1994). 
Their production is pathogen-dependent. Produced by Th1 cells, IFN-γ for example is 
the strongest activator of macrophages and is secreted by themselves as well (Getz, 
2005; Lohmann-Matthes et al., 1994). Macrophages need it to boost their MHC II 
molecules (Getz, 2005; Jansen, 1996), and for further secretion of IL-6, TNF-α and IL-1 
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which have pro-inflammatory roles (Getz, 2005). In contrast, IL-12 and IL-18 support 
differentiation of T cells into Th1 profile (Getz, 2005; Peters-Golden, 2004). There is 
evidence that healthy individuals exhibit higher levels of these two interleukins than 
humans with allergic asthma (Peters-Golden, 2004). Moreover, IL-12 and IL-18 induce 
IFN-γ secretion by NK and T cells (Getz, 2005). Finally, TGF-β together with IL-10 
show opposing effects. They possess the strongest capacity to deactivate macrophages, 
despite these cells generate them on their own (Lohmann-Matthes et al., 1994). This 
mechanism of self-deactivation is still an unanswered question. Furthermore, they are 
capable of dampening Th1 and Th2 responses, respectively (Peters-Golden, 2004). 
Their course of action is conditional on the circumstances, hence they are also referred 
to as “regulatory cytokines” (Peters-Golden, 2004). In particular IL-10 has been 
reported to play a role in immunologic tolerance, as it is expressed by regulatory T cells 
(Kuipers and Lambrecht, 2004; Lambrecht, 2005; Peters-Golden, 2004; Upham and 
Stumbles, 2003). Beside the cytokines, macrophages also produce substances like nitric 
oxides (NO) (Holt, 2000; Peters-Golden, 2004), oxygen radicals (Lohmann-Matthes et 
al., 1994) and metabolites of arachidonic acid like PGE2 (prostaglandin E2) and PGD2 
(Lohmann-Matthes et al., 1994; Peters-Golden, 2004). NO on the one hand favours Th2 
immunity (Peters-Golden, 2004), on the other hand, it is able to inhibit T cell responses 
(Holt, 2000; Peters-Golden, 2004). Moreover, it has the ability to interrupt the 
amplification of APC function of lung DCs that is GM-CSF-dependent (Holt, 2000). 
Similarly, PGE2 has been attributed a pro-inflammatory activity due to its tendency to 
cause edema, however, recently, its bronchodilatory effect has been documented 
(Peters-Golden, 2004).  
 
In summary, the role of macrophages in immune responses can be described as a 
regulatory and sometimes even protective one. Unfortunately, this cell population does 
not raise as much curiosity and interest as DC do, and therefore remains poorly 
investigated issue.  
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1.7   THE AIM OF THE STUDY 
 
The goal of this project was to specify and describe a particular population of lung cells 
that, after the intranasal administration, pick up the antigen and store it for uncertain 
periods of time. In order to visualize the cells, OVA antigen conjugated to red 
fluorochrome TexasRed (TR-OVA) and AlexaRed, respectively, was used. 
 
Mice with naïve background were healthy animals who had no preliminary contact with 
OVA, while in rechallenged and recovered mice allergic pulmonary response to this 
antigen was initiated. For the purpose of eliciting asthmatic immune reaction, animals 
from latter two groups were twice systemically primed with OVA injections. 
Subsequently, inhalative challenge with nebulized OVA was conducted. Six months 
later, naïve as well as rechallenged group representatives were intranasally administered 
TR-OVA. Consequently, the cells taking up the antigen were tracked in these two 
groups. Recovered models served as control mice, since they had not received any 
further treatment with TR-OVA in order to resolve asthmatic condition. Hence, the 
intention was not only to characterize the morphology and location of those cells, but 
also to compare these cells in mice encountering the antigen for the first time to those 
who have been systemically sensitized to the antigen and have developed immune 
response as consequence.  
In order to analyse the cells containing fluorescent material, lungs were obtained and 
frozen seven days after the i.n. instillation of antigen. Subsequently, techniques of 
immunohistochemistry were performed on frozen lung tissue sections. The 
immunofluorescence staining was targeted at cell surface markers characteristic for 
APCs implicating CD11b, CD11c, B220, F4/80, and CD4, which is specifically 
expressed by T cells. Following microscopic analysis provided insights and findings 
needed to establish the phenotype of the cells including morphology, localization, 
distribution, amount in comparison to other cell populations, and eventually the 
function. 
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Transgenic GFP-DTR mice 
 
Concerning the animals used, it is necessary to note that beside the wild type also 
transgenic mice were implied. These rodents were DTR-GFP mice, what means 
transgenic mice expressing the diphtheria toxin receptor (DTR) and green fluorescent 
protein (GFP) driven by the CD11c promoter. The purpose for their use has been 
reported by Steffen Jung and colleagues (van Rijt et al., 2005). In their study, van Rijt,  
Jung et al. documented the ability to deplete lung CD11c+ DC and alveolar macrophages 
from airways of DTR tg mice as a result of administration of diphtheria toxin (DT). 
Normally, mice are unsusceptible to DT due to the missing DT receptor. CD11c-DTR 
mice, however, prove the opposite. With the administration of DT to airways of 
previously OVA-sensitized mice, lung CD11c+ cells were eliminated. Subsequently, 
mice were again exposed to aerosolized OVA, however they did not respond to the 
antigen with cytokine secretion by Th2 cells. Moreover, major events of asthmatic 
inflammation were resolved. In the further course, adoptive transfer of CD11c+ DC 
caused the recurrence of the disease events. Transfer of CD11c+ macrophages failed to 
re-establish the disease. In summary, their experiment demonstrated that lung CD11c+ 
DC are required for the induction of Th2-guided asthma in mice and emphasized their 
significance for the therapeutical directions. 
  
In this study, CD11c-GFP-DTR mice were used in order to verify if GFP+ cells, that 
also express CD11c marker, co-localize with cells that pick up and retain fluorescent 
TR-OVA antigen.  
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2.   MATERIALS AND METHODS 
 
 
2.1   MICE STRAINS 
 
The project involved wild type BALB/c and C57Bl/6 strains. Furthermore, BALB/c 
transgenic mice expressing diphtheria-toxin-receptor (DTR) and green fluorescence 
protein (GFP) driven by CD11c promotor were used. The rodents were housed under 
standard conditions at the animal facility of VIRCC in Vienna, Austria, with the 
permission of the Animal Ethics Committee of Medical University of Vienna.  
 
 
 
2.2   MOUSE MODELS 
 
For the experiment three following groups with mice were established: 
 
1. “Naïve mice”: Naïve wild-type and naïve transgenic GFP-DTR mice were 
anaesthetized with 100µl of a composite containing 2ml Rompun® (Bayer) and 
10ml Ketanest® (Pfizer) diluted in 18ml distilled water. Afterwards they were i.n. 
administered 100µg OVA-Alexa Red (OVA conjugated to AlexaFluor 594) or 
OVA-Texas Red (both from Molecular Probes).  
 
2. “Memory mice”: In order to induce allergic asthma in mice, this group (WT and 
TG-animals) was twice immunized with i.p. injection of 10µg OVA on days 0 and 
21. Subsequently they were treated with 1% aerosolized OVA on day 28. Six 
months later, when mice already had recovered from the acute disease, they were 
rechallenged with i.n. instillation of 100µg OVA conjugated to Texas Red (TR-
OVA) under preceded anaesthetization. 
 
3. “Recovered mice”: Like in the previous “memory” group, here again WT-mice and 
TG-rodents received separately two doses of 10µg OVA i.p., on days 0 and 21. 
Aerosol challenge with 1%OVA followed on day 28. To be able to recover from 
46 
acute allergic response, these mice had no further treatment with OVA-TexasRed 
allergen and had to rest for at least four months before removing their lungs. 
 
Recovered mice as well as the naïve mice served as a control group in the experiment. 
 
 
 
2.3 ISOLATION OF LUNGS 
 
One week after the i.n. instillation, mice were put down by a lethal dose of anaesthetic. 
Lungs were taken out and were inflated and perfused with 1ml 40% OCT diluted with 
autoclaved water. Embedded in OCT, lung blocks were frozen on dry ice and kept at -
20°C. 
 
 
 
 
2.4 IMMUNOHISTOCHEMISTRY 
 
2.4.1 Antibodies 
 
For immunofluorescence staining methods either directly fluorescence-conjugated or 
purified primary monoclonal antibodies accompanied by fluorescence-conjugated 
secondary antibodies were applied.  
 
 
Primary antibodies: 
 
Directly conjugated to fluorochrome: 
•  anti-CD11c-FITC    BD Pharmingen 
•  anti-CD11b-FITC    BD Pharmingen 
•  anti-CD4-FITC    BD Pharmingen 
•  anti-GFP AlexaFluor 488   Molecular Probes 
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Purified: 
•  anti-CD11c (hamster)   BD Pharmingen 
•  anti-CD11b (rat)    BD Pharmingen 
•  anti-CD4 (rat)    BD Pharmingen 
•  anti-B220 (rat)    BD Pharmingen 
•  anti-F4/80 (rat)    Serotec  
 
 
Secondary antibodies: 
•  Goat-anti-hamster IgG AlexaFluor 488  Molecular Probes  
•  Goat-anti-rat IgG AlexaFluor 488  Molecular Probes 
 
 
 
 
2.4.2   Immunofluorescence staining of frozen sections 
 
Frozen lung blocks were cut on a Cryotom (Leica) in 4µm sections, they were placed on 
a glass slide and stored at -20°C. The frozen sections were then defrosted for 10 min at 
room temperature before being fixed in acetone for another 10 min at 4°C. After 
washing them in PBS, the slides were then incubated with 100µl of diluted primary 
antibody per section for 60 min at 37°C in dark. In case of using purified primary 
antibodies, sections were first washed with PBS and then incubated with diluted 
secondary antibodies conjugated to detectable fluorochrome for further 30 min at room 
temperature in dark. When the incubation processes were all completed, the slides were 
washed in PBS and afterward in distilled water. As last step they were embedded with 
Fluorosave (Molecular Probes). The staining was analyzed with a Nikon Optiphot 2-UD 
fluorescence microscope and digital camera using a Multiband Filtersystem including 
red, green and triple filter at 40x and 20x magnification. 
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2.4.3  Haematoxylin staining 
 
Haematoxylin is a dye that is widely-used in histological analysis for staining of 
basophilic cell components such as cell nuclei. For the microscopic examination of 
frozen lung sections from mice haematoxylin was necessary to highlight whether the 
cells being tracked are located in the parenchymal tissue and if they were in the central 
part of the lung lobe or rather in the periphery. For this purpose, slides were stained for 
15 seconds with haematoxylin either before or after incubating them with the antibodies. 
The latter option proved to be more efficient and was applied further on.  
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3.   RESULTS  
 
  
3.1   LUNG CELLS ENGULFING INHALED OVA ANTIGEN: TR-OVA+ CELLS 
  
To visualize and study the cells ingesting the inhaled OVA antigen in the lung, mice 
were given AlexaRed-OVA or TexasRed-OVA i.n. (these cells are from here on 
referred to as TR-OVA+ cells). After seven days lungs were isolated and frozen for 
further immunofluorescent analysis. 
 
The figure below shows pictures of frozen lung tissue sections of naïve and 
rechallenged (memory) animals. The ingested OVA antigen conjugated to the red 
fluorochrome is represented by red patches in the tissue. The pictures used demonstrate 
the average impression of lung sections that have been examined under the microscope. 
In other words, the distribution of TR-OVA+ cells was not equal throughout the entire 
lung. Regions were found where barely any or even none red spot was sighted. In 
contrast, some areas were truly “invaded” by the red signals, what will be shown later. 
Nevertheless, the TR-OVA+ cells seem to be large cells with irregular shape and unclear 
surface. Their bright red signal appears as punctate within the cell. They appear as 
single cells. As shown here, no difference concerning TR-OVA+ population could be 
discovered between naïve and memory mice lungs. 
   
 
 
 
 
 
 
           
A B 
Figure 1. Frozen lung sections of naive (A) and rechallenged (B) mice treated with TR-OVA 
antigen. Pictures illustrate parenchymal lung compartments with red fluorescent TR-OVA+ cells. They 
are distributed throughout the tissue with bias for air spaces. Due to the performed haematoxylin staining 
of rechallenged section (B), red TR-OVA+ signals do not appear as bright as in the naive sample.  
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3.2  TR-OVA+ CELLS AFTER STAININIG WITH ANTIBODIES 
 
In order to characterize the cells picking up the allergen and to find out something about 
their appearance and localization in the lung, frozen lung sections were examined by 
means and methods of immunohistochemistry. Frozen slides with lung tissue of naïve, 
rechallenged (memory) and recovered (no TR-OVA treatment) mice were stained with 
fluorescence-labelled antibodies. The staining was directed against cell surface markers 
specific for APCs involving CD11b, CD11c, F4/80, and B220, but also against marker 
specific for T lymphocytes like CD4. Moreover, the antibody anti-GFP was applied 
exclusively for staining sections of transgenic GFP-DTR mice. 
 
 
 
 
3.2.1 TR-OVA+ cells are CD11b-  
 
First immunofluorescent staining was performed with anti-CD11b antibody. The 
intention was to verify whether TR-OVA+ cells co-express CD11b surface marker which 
is in first line specific marker for macrophages but it can also be found on some DCs. 
For that purpose lungs from naïve models as well as from mice with memory disease 
that have been treated with TR-OVA or AR-OVA, respectively, were harvested and 
frozen. The slides with tissue were stained either with anti-CD11b-FITC monoclonal 
antibody or with purified anti-CD11b rat primary antibody followed by secondary 
fluorescent Ab goat-anti-rat IgG AF488 for detection. Few of the slides were 
subsequently dyed with haematoxylin. The first impression of this staining revealed that 
TR-OVA+ cells are negative for CD11b marker, even though the two cell populations 
(TR-OVA+ and CD11b+) are situated very close to each other. In this regard, the 
assistance of haematoxylin, which stains the cell nuclei in particular, allowed the 
observation that TR-OVA+ cells were not placed in proximity of cardinal respiratory 
bronchi or main pulmonary vessels but they were rather located in the lung periphery. 
As evidenced in the figure below, both cell subsets reside around the airway and are 
similar in size, namely extraordinary large. In addition, it seems like the red single 
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positive TR-OVA cell is positioned in the alveolar space (arrow). Apart from that, 
CD11b+ cells form clusters. 
 
 
 
A B 
C D E
Figure 2. Naive lungs stained with haematoxylin and anti-CD11b Ab (A-E). Slides were first stained 
with pure anti-CD11b monoclonal Ab followed by secondary green fluorescent goat-anti-rat IgG AF488. 
In addition, sections were dyed with haematoxylin. Triple filter visualization evidences the close 
proximity but no co-localization of TR-OVA+ signals seen in red and CD11b+ cells shown in green (B-E). 
Without triple filter (A), the vicinity of TR-OVA+ population to airways is even more apparent.  
 
 
 
Comparing the naïve tissues with the memory sections, the TR-OVA+ profile was 
virtually the same. At first view it is obvious that the image of naïve mice beneath 
exhibits a greater number of both, TR-OVA+ and CD11b+ signals, what would rather 
have a conflicting notion. However, the image above disproves that claim, since it 
displays a naïve model bearing fewer cells of both populations. Thus, again it is 
apparent that spatial dispersion of TR-OVA+ as well as CD11b+ cells is not constant 
within distinct sectors of the lung.  
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Figure 3. Sections with naive (D-I) and rechallenged lung tissue (A-C) stained for CD11b marke
 
(A-I). Staining was performed with purified anti-CD11b mAb and subsequently with AF488-labelle
.2.2 TR-OVA+ cells are CD11c+ 
xcept from macrophages, DCs are also found to express the surface marker CD11c. In 
A C 
D E F 
G H I 
B 
r 
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goat-anti-rat Ab. Cells with ingested red TR-OVA antigen are often positioned next to green single 
positive CD11b cells as well as to clustered green CD11b+ population, as seen here in a naive slide (G).   
  
   
 
 
 
3
 
E
order to verify whether TR-OVA+ cells co-express this marker, lungs of naïve models 
and mice with memory disease were stained for CD11c. Thereto, anti-CD11c-FITC was 
used or the other option was the incubation with pure primary hamster anti-CD11c 
antibody followed by fluorescent secondary goat-anti-hamster IgG AF488. As the 
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images below prove, TR-OVA+ cells co-localize with the CD11c+ staining. Single TR-
OVA+ signal is seen in red and single CD11c+ cells appear green. Double positive (TR-
OVA+CD11c+) signals appear yellow-orange (white arrow). All three cell types (single 
TR-OVA+, single CD11c+ and double positive TR-OVA+CD11c+) are spread through 
the alveoli tissue with a bias for air spaces and airways. In this regard, there is one 
distinctive feature noticed in naïve model, and that is single TR-OVA+ red signal within 
the air space (violet arrow), neither single positive CD11c cells nor double positive 
signals were sighted within alveoli. However, it has to be noted that TR-OVA+ cells 
were found within the alveoli in rechallenged mice as well and this will be shown later. 
CD11c+TR-OVA- population occurs in clusters, whereas single TR-OVA+CD11c- and 
double labelled TR-OVA+CD11c+ cells do not share this manner. When comparing the 
number of stained cells, it can be stated that single positive TR-OVA red cells and single 
positive CD11c green cells are balanced, it is however mentionable that the percentage 
of double labelled population is very low. Concerning these observations, naïve and 
memory mice are found to be similar. As to the dimension of stained cells, the three 
subsets resemble each other in size. In terms of the shape, CD11c+ cells do not indicate 
a particular form neither, the difference to the TR-OVA+ signals however is that CD11c 
stains the cell surface, whereas TR-OVA stain is kept intracellular.  
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Figure 4. Naive and rechallenged lung compartments stained for CD11c marker (A-F). Mice were 
administered TR-OVA Ag i.n. and lungs were taken out and frozen. Slides were stained with anti-CD11c-
FITC fluorescent Ab. Sections from both mice groups, naive (A-C) as well as rechallenged (D-F), 
demonstrate co-localization of red TR-OVA stain and green anti-CD11c molecules and these double 
labelled signals are recognized as yellow-orange cells.  
 
 
 
 
 
 
 
3.2.3 TR-OVA+ cells are F4/80+ 
 
The next immunofluorescence staining was targeted at F4/80, which is identified as 
macrophage cell surface marker. To examine them under the microscope, frozen lung 
tissues of naïve and rechallenged mice were first stained with anti-F4/80 rat primary 
antibody and as a detecting secondary antibody goat-anti-rat IgG AF488 was used. The 
figures below evidence that TR-OVA+ cells co-express the F4/80 marker. Sole TR-
OVA+ signal is shown in red colour and single F4/80+ cells are represented in green. 
Double labelled TR-OVA+F4/80+ cells appear yellow-orange. Comparing the amount of 
the stained cells, it is obvious that there are more green single positive F4/80 cells than 
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red cells that have engulfed the TR-OVA antigen. The most slender population is the 
double positive yellow-orange TR-OVA+F4/80+ subset. In this matter naïve and 
rechallenged models exhibit identical pattern. Single TR-OVA+ cells and sole F4/80+ 
cells are similar in size, large that is. The other common morphological feature of these 
two subsets is the undefined shape, however, not to forget is the fact that F4/80 stains 
extracellular and TR-OVA is positioned inside the cell. In regard to the localization, all 
three populations are dispersed through the parenchyma tissue in the lung periphery, 
particularly focussed on airways. In this context there is some noteworthy similarity 
affecting localization of TR-OVA+ signals in naive and memory mice. Looking at the 
images below, naïve model shows all three cell types near the airways. In contrast, 
memory mice indicate double labelled TR-OVA+F4/80+ signal not only around but 
within the air space as well (arrow). This occurrence has been detected in naïve model 
before, even though it evidenced single positive TR-OVA red cell within the alveoli. 
Here, during the F4/80 staining, it is probably a coincidence that no single positive TR-
OVA or double labelled cells were found within the airway in naïve mice. Apart from 
that, memory model highlights a kind of cluster containing double positive TR-
OVA+F4/80+ signals, which does not look cluster-like but rather like a row of cells 
attached to one another. Unfortunately, this occurrence has been a non-recurring unique 
observation and does not conform to the average findings from rechallenged mice.  
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Figure 5. Frozen sections from naive and rechallenged mice lungs stained with anti-F4/80 Ab (A-F). 
Tissue compartments were incubated with primary anti-F4/80 Ab and for detection, goat-anti-rat attached 
to green fluorochrome AF488 was applied. Double labelling is evidenced in naive (A-C) as well as 
rechallenged lungs (D-F), and appears in yellow-orange. Apparently, double positive signal (TR-
OVA+F4/80+) is resident except from tissue also in the air space of rechallenged mouse model (D). 
 
 
 
 
3.2.4 TR-OVA+ cells are negative for B220 marker 
 
As B220 is defined as a cell surface marker for B cells, although there are reports 
claiming that certain subset of DCs also express B220, and since B cells beside DCs and 
macrophages also belong to APCs, the immunohistological examination with 
fluorescent antibodies included anti-B220 staining as well. For that purpose frozen 
slides with sections of naïve and rechallenged animals were incubated with anti-B220 
rat primary antibody and subsequently they were stained with fluorescent secondary 
antibody goat-anti-rat IgG AF488. The pictures demonstrate that B220+ green staining 
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does not co-localize with TR-OVA+ red signal, no double positive cells were found. 
Comparing the number of the two cell populations stained, it can be seen that in 
rechallenged models the TR-OVA+ and the B220+ cells are in balance, naïve models 
however display more red TR-OVA+ signals than B220+ green cells. Here, it is 
necessary to allude that in naïve mice the opposite has been noted as well, this means 
there were areas in naïve mice where B220+ population was in superior number 
compared to cells that have picked up the TR-OVA particles, in other words both cell 
types occur in related quantity. The general impression however, was that rechallenged 
models exhibited a greater amount of B220+ cells but the number of TR-OVA+ signals 
was similar to naïve sections. As to the site of their disposition, the two subsets are 
distributed throughout peripheral regions in the lung. Again both cell types demonstrate 
their close proximity to the airways and to each other (arrow). The cells positive for 
B220 appear in different sizes, from tiny to midsize, but they are generally smaller than 
TR-OVA+ cells. Regarding the shape, the majority of B220+ cells are, unlike the TR-
OVA+ cells, round or oval.  
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Figure 6. Anti-B220 staining of lung tissue from naive (A-C) and rechallenged mouse models (D-F). 
Slides were stained with anti-B220 Ab and afterwards with AF488-labelled goat-anti-rat green fluorescent 
Ab. Both mice groups exhibit no double labelling of green B220+ cells with cells that have taken up OVA 
antigen attached to red fluorochrome TR.  
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3.2.5 TR-OVA+ cells are negative for CD4 marker  
 
CD4 is a cell surface marker mainly expressed by T-helper cells, but macrophages also 
have low expression. The staining was performed with naïve and rechallenged animals. 
For the microscopic examination, frozen sections were stained with anti-CD4-FITC 
fluorescent antibody, unfortunately without great success, or purified primary rat 
antibody anti-CD4 in combination with secondary Ab goat-anti-rat IgG AF488 were 
applied and achieved respectable results. The analysis revealed that the CD4+ staining 
did not co-localize with the TR-OVA+ red signal. In terms of localization, both cell 
types are dispersed through the parenchymal structures preferring the direct vicinity to 
the airways. Concerning this matter, there was not any discrepancy among naïve and 
rechallenged mice. Although the two cell populations are sometimes situated relatively 
proximal to each other, they are not as close as observed in CD11b staining where the 
vicinity of TR-OVA+ signals to single and accumulated CD11b+ cells was obvious. 
Further, the figure below shows that cells which have taken up the TR-OVA antigen 
differ in size and shape from CD4+ cells. Unlike TR-OVA+ profile, the CD4+ cells are 
small and round or egg-shaped, with a smooth surface. TR-OVA+ cells, in contrast, are 
large cells without well-defined shape and the nature of their cell surface is not 
sufficiently visible and remains dubious. Nevertheless, the circumstance that in the 
images below the naïve models display a bigger amount of CD4+ cells that are beside 
the single occurrence also aggregated in nuggets, does not represent the totality of the 
stained sections. Such CD4+ distribution pattern was observed in the rechallenged 
models as well, however the pictures were selected due to the quality and the phenotype 
of CD4+ staining was similar in both mice groups.  
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Figure 7. Lung compartments of naive and rechallenged mice stained for CD4 marker (A-F). Frozen 
sections were incubated with pure anti-CD4 mAb and subsequently were stained with secondary goat-
anti-rat AF488 Ab. Neither naive (A-C) nor rechallenged lungs (D-F) reveal co-localization of red 
fluorescent TR-OVA+ signals with green cells positive for CD4 marker.   
 
 
 
 
 
3.2.6  TR-OVA+ cells do not co-express GFP-DTR 
 
In the project, beside the wild-type mice, transgenic mice were also used. These express 
the green fluorescent protein (GFP) and diphtheria toxin receptor (DTR) and this 
process is regulated by the CD11c promoter. In order to test whether cells with GFP-
DTR co-localize with the TR-OVA+ signal, the slides with naïve and rechallenged 
tissues were stained with anti-GFP AF488 antibody. Unfortunately, the pictures are not 
in high quality. Due to the weak green fluorescent signal, it was sometimes difficult to 
find which cells were actually stained. Nevertheless, the pictures shot were still 
sufficient to provide evidence that TR-OVA+ do not co-localize with GFP+ staining, no 
double labelled cells were detected. The green GFP+ cells are like TR-OVA+ cells large 
and with irregular shape. Another common property is the localization, GFP+ subset is 
also present near the airways in peripheral areas of lungs. In terms of the amount the 
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impression was that GFP+ population appeared in bigger numbers than TR-OVA+ 
subset. This disparity was observed in both mice groups, naïve as well as memory 
disease. In addition, the figures illustrate GFP+ cells clumping together to clusters, a 
feature which does not match into the TR-OVA+ cells phenotype. 
 
 
 
A C B 
 
D E F 
Figure 8. Lung tissue of transgenic GFP-DTR mice stained for anti-GFP (A-F). Staining was 
performed with anti-GFP AF488 green fluorescent Ab. As evident, no double labelling was observed. 
Cells with internalized TR-OVA are represented in red and GFP+ cells appear in bright green fluorescent 
signals. The two cell types are in close proximity to each other (arrow) like rechallenged mouse sample 
demonstrates (D). Naive mice show green GFP+ cells accumulated to cluster (A, B). 
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4. DISCUSSION 
 
The intent of this project was to ascertain and characterize the pattern of a cell 
population in the lung of mice that ingest and hold OVA antigen one week after the 
intranasal administration. To be able to visualize those ingesting cells, the OVA antigen 
conjugated to a fluorochrome Texas Red was used. Beside the microscopic analysis that 
provided us an insight into their morphology and localization, we applied methods of 
immunohistochemistry to upgrade the phenotype and gain indication of their potential 
function. Accordingly, immunofluorescent staining was targeted against cell surface 
markers specific for T cells and APCs including: macrophages, DCs and B cells.   
 
 
Phenotype of TR-OVA+ cells  
 
In our study, we detected the labelled antigen kept in cells in mouse lungs even seven 
days after the intranasal instillation. These cells, referred to as TR-OVA+ cells, are large 
in size and do not have an accurately defined shape. Their surface also remained 
unclear. Further, we assessed that the fluorescent signal appeared spotted throughout the 
cell. One possible explanation could be that the engulfed fluorescent antigen was 
fragmented to a certain degree. It would be interesting to track and examine these cells 
in recovered animals after three to four months for instance. In terms of the localization, 
TR-OVA+ cells were situated in the lung periphery, particularly in close proximity to 
airways but red fluorescent signals were observed within the airways and alveolar 
spaces as well. The distribution however was not constant within the entire parenchymal 
tissue. Alveolar tissue compartments have been regarded where no red fluorescent 
signal was sighted. One of the reasons could be the low and insufficient concentration of 
antigen that was administered, the other cause might be that instilled antigen is not 
equally transported to all sections of the lung (Vermaelen et al., 2001), or, the 
distribution of APCs is not consistent throughout the lung tissue due to the complex 
association to their function (von Garnier et al., 2005). In addition, there was no 
evidence of aggregating to clusters, TR-OVA+ signals appeared as single cells.  
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The performed immmunofluorescent staining ought to give us information about cell 
surface markers TR-OVA+ cells express, according to which we attempted to classify 
them. The first significant finding was that TR-OVA+ subset is positive for CD11c, even 
though the double-labelled population appeared in slight amount. All the more, it was 
surprising that TR-OVA+ cells were negative for GFP, as we expected to see the 
opposite. The subsequent simultaneous staining of GFP-DTR mice lung sections with 
anti-CD11c and anti-GFP fluorescent antibodies was not less disputed. It evidenced that 
GFP+ cells moderately co-expressed CD11c marker, the double positive population of 
CD11c+GFP+ cells was represented by a short number (data not shown). The reason for 
this is unknown. Nevertheless, our findings suggest four different populations of 
CD11c+ cells involving CD11c+TR-OVA+, CD11c+TR-OVA-, CD11c+GFP+ and 
CD11c+GFP- population. Hence, these discrepancies require further experiments to 
clarify the relation among those four subsets. However, for our project the one 
population of CD11c+TR-OVA+ cells was solely important. The CD11c marker is 
proved to be variably expressed on lung resident DCs and alveolar and interstitial lung 
macrophages as well (Cleret et al., 2006; Gonzalez-Juarrero and Orme, 2001; van Rijt et 
al., 2005). Similarly, the CD11b cell marker is expressed by myeloid DC (Byersdorfer 
and Chaplin, 2001; von Garnier et al., 2005) and lung macrophages (Strauss-Ayali et al., 
2007; von Garnier et al., 2005). However, we could demonstrate that cells picking up 
fluorescent OVA antigen are negative for CD11b, and according to this evidence we 
could exclude that they might be conventional DCs. With these results the phenotype of 
our TR-OVA+ cells was equalized between subsets of DCs and macrophages. After we 
additionally verified the co-localization of TR-OVA+ with F4/80+ staining, the balance 
moved towards lung macrophages, as this marker is known to be specific for 
macrophage lineage cells (Gonzalez-Juarrero et al., 2003; Morris et al., 1991). However, 
previous studies have reported on DCs that do express F4/80 antigen as well (Belz et al., 
2004; Gonzalez-Juarrero and Orme, 2001). In the further run of the project, we 
ascertained that cells engulfing TR-OVA are B220-, thus they are neither B cells, nor 
they correspond to plasmacytoid DC phenotype (Martin et al., 2002). Besides that, 
according to the CD4 staining, we not only detected that our TR-OVA+ do not express 
CD4 marker, but we also observed that our red fluorescent cells are not placed that near 
to clusters of CD4+ cells, which we supposed to be T helper cells. Furthermore, no TR-
OVA+ signals were found in close vicinity to huge accumulation of T helper cells 
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around the airways that are probably infiltrates (data not shown), suggesting that there is 
no interplay among these two cell types.  
 
In this context, we determined no significant differences between naïve models and 
rechallenged mice with memory disease. We compared diverse patterns of the TR-
OVA+ subset involving distribution throughout distinct sections of the lung with 
confinement to lung parenchyma, localization in the tissue with preferred proximity to 
airways, lacking ability of forming clusters, and finally, very similar amount of cells in 
both mouse systems. Of course, this latter observation is an impression limited by the 
fact that it is based on individual human sense. Hence, it demands further reliable 
quantitative analysis provided by FACS. A recent study, for example, reported on a 
CD11b-CD11c+ population consistent with our TR-OVA+CD11b-CD11c+ subset 
(Gonzalez-Juarrero et al., 2003). They identified it as a mixture of alveolar macrophages 
and immature DCs, whose cell numbers decreased during the development of an 
infection. The reason for this was the change in the expression of these two cell surface 
markers upon the early and chronic disease, and they suggest that this changing 
phenotype was due to the differentiation of those cells. Unfortunately, we do not have 
sufficient data to confirm whether this did or did not happen in our mouse models. 
Furthermore, concerning the other single stained cell types which did not contain the red 
OVA antigen, including CD11b+, CD11c+, GFP+, F4/80+ and CD4+ subsets, we noticed 
no disparities in cell amounts comparing naïve and memory animals. Only the B220+ 
staining showed a slight discrepancy among the two animal groups, namely, the 
rechallenged group exhibited just a bit more B220+ cells than the naïve rodents. Thus, 
on the one hand, we established that the accumulation of cells addressed, representing 
APCs and T helper cells, as well as the single stained TR-OVA+ signals, occurred to 
closely related extent, reflecting that even naïve animals who had never encountered 
TR-OVA antigen before, were probably able to develop immune response to this 
antigen even without prior systemic sensitization. On the other hand, the B220 staining 
results generated suspicion and doubt on our opinion. Therefore, it would be advisable 
to verify this assumption with approved and appropriate methods and examine the 
common hallmarks of asthmatic disorder, such as IgE production and eosinophilic 
inflammation, analyze the mucus hypersecretion, and test the AHR.  
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To conclude, although more indications argue for macrophages, it would be premature 
to define TR-OVA+ as their subset. Indeed, cells taking up red OVA allergen share 
morphological profile as well as localization pattern with macrophages. Both cell types 
are large and are situated close to airways but also within alveolar spaces. However, in 
terms of the function, here, we could not actually determine what role TR-OVA+ cells 
play in the immunologic processes. What is for sure is that our cells engulf the antigen 
but do not process it or they process it to a low degree. According to this, we do not 
believe they present the antigen to T cells. Additionally, this notion was further 
supported by the fact that we did not observe TR-OVA+ cells in close proximity neither 
to CD4+ single cells and/or clusters nor to the infiltrates of CD4+ T cells. Unlike this, 
researchers have described a subset of BAL DCs with CD11c+CD11b+ phenotype that 
pick up antigen and retain it for up to three weeks after the inhalation, these cells 
however were proved to highly present the antigen (Julia et al., 2002). They also 
identified a subset of CD11c+CD11b- cells, what matches into the phenotype of our TR-
OVA+ cells, but these were not capable of capturing the antigen efficiently. Though, at 
this point it is important to note that this group used much lower concentration of 
antigen, so this might be the reason for not retaining it. Other group, for instance, 
characterized cells taking up fluorescent latex beads, either with or without conjugated 
OVA antigen, as CD11c+CD11b-F4/80+ subset of airway DCs (Byersdorfer and 
Chaplin, 2001). Their experiment however differs from ours as they exclusively 
examined BAL cells and we investigated tissue compartments. Another distinction is the 
timepoint, they tested the antigen uptake 6 h and 48 h after the administration, we 
analyzed seven days after the instillation. Hence, we realize it is not easy to compare 
results because there are so many diverse factors that need to be considered and limit the 
comparison. One last example of a study that achieved results conforming to ours, 
reported on a long-lived cell population with high endocytic capacity. Von Garnier et al. 
(2005) identified those cells as lung resident tissue macrophages being positive for 
CD11c and F4/80 expression and negative for CD11b marker. Moreover, this 
population appeared incapable of stimulating the T cells in vitro or initiating their 
proliferation, in contrast, it indicated rather potential suppressive activity. This latter 
discovery we could not reconcile with our results as we did not performed such 
attempts. However, the outcome from this study was very close to ours and provides 
valuable proposals. 
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Nevertheless, in the end, dealing with so many similar and differing data, controversial 
findings, it remains impossible to assign our red fluorescent TR-OVA+ population either 
to DCs or to macrophages. Perhaps they are precursor cells in a late monocytic stage, 
something like indeterminate cells, which differentiate in the tissue either into 
macrophages or into DC. It is known that macrophages and DCs may arise from 
common precursor state (Goldsby et al., 2001; Gonzalez-Juarrero et al., 2003). 
Therefore, as long as they are immature, the internalized antigen stays non-degraded. 
Like mentioned before, it would be interesting to pursue these cells for extended periods 
of time, what would mean to track them in recovered animals. To date, it remains 
unknown what happens with the deposits of ingested antigen.  
 
Taken together, we investigated a population of lung resident cells that take up OVA 
antigen conjugated to red fluorochrome after the intranasal administration and keep it 
for at least seven days. They demonstrate a CD11c+CD11b-F4/80+ phenotype, that is a 
mixtured phenotype of lung DCs and macrophages. In the experiment, there was no 
evidence of antigen presentation to T cells. Further studies need to be done in order to 
understand their development and ascertain their function in allergic reactions. 
According to our findings, we assume TR-OVA+ cells constitute an intermediate subset 
with phenotype common for both, DC and macrophages.  
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